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Abstract 
 
 
The distinction of Parkinsonian Syndromes (PS) is challenging due to similarities of symptoms 
and signs at early stages of disease. Thus, the need of accurate methods for differential 
diagnosis at those early stages has emerged. To improve the evaluation of medical images, 
artificial intelligence turns out to be a useful tool. Parkinson’s Disease, the commonest PS, is 
characterized by the degeneration of dopamine neurons in the substantia nigra which is 
detected by the dopamine transporter scan (DaTscanTM), a single photon-emission tomography 
(SPECT) exam that uses of a radiotracer that binds dopamine receptors. In fact, by using such 
exam it was possible to identify a sub-group of PD patients known as “Scans without evidence 
of dopaminergic deficit” (SWEDD) that present a normal exam, unlike PD patients. In this 
study, an approach based on Convolutional Neural Networks (CNNs) was proposed for 
classifying PD patients, SWEDD patients and healthy subjects using SPECT and Magnetic 
Resonance Imaging (MRI) images. Then, these images were divided into subsets of slices in 
the axial view that contains particular regions of interest since 2D images are the norm in 
clinical practice. The classifier evaluation was performed with Cohen’s Kappa and Receiver 
Operating Characteristic (ROC) curve. The results obtained allow to conclude that the CNN 
using imaging information of the Basal Ganglia and the mesencephalon was able to distinguish 
PD patients from healthy subjects since achieved 97.4% accuracy using MRI and 92.4% 
accuracy using SPECT, and PD from SWEDD with 97.3% accuracy using MRI and 93.3% 
accuracy using SPECT. Nonetheless, using the same approach, it was not possible to 
discriminate SWEDD patients from healthy subjects (60% accuracy) using DaTscanTM and 
MRI. These results allow to conclude that this approach may be a useful tool to aid in PD 
diagnosis in the future.  
 
Keywords: Parkinsonian Syndromes Classification - SWEDD - DatScanTM - MRI – 
Convolutional Neural Networks 
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Resumo 
 
 
 
A distinção de Síndromes Parkinsonianos (SP) tornou-se um desafio dado que os sintomas e 
os sinais característicos destas doenças são muito semelhantes entre si nas fases iniciais. Assim 
surge a necessidade da criação de métodos precisos para um diagnóstico que as diferencie. 
Uma possível solução é o recurso à inteligência artificial que se tem vindo a tornar numa 
ferramenta útil para a melhoria da interpretação das imagens médicas. A doença de Parkinson 
(DP), a SP mais comum, é caracterizada pela neurodegeneração dos neurónios 
dopaminérgicos. Esta neurodegeneração é detetada pelo DaTscanTM, um exame de tomografia 
computorizada por emissão de fotão único (do inglês Single-Photon Emission Computed 
Tomography, SPECT). A utilização deste exame permitiu a identificação de um subgrupo de 
pacientes diagnosticado com DP, denominados de “exames sem evidência de défice 
dopaminérgico” (do inglês “Scans without evidence of dopaminergic deficit”, SWEDD). Os 
SWEDD são pacientes que possuem um DatScan normal ao contrário dos pacientes com PD. 
Nesta dissertação, é proposta uma abordagem com recurso às redes neurais convolucionais (do 
inglês: Convolutional Neural Networks, CNNs) usando imagens SPECT e Imagens por 
Ressonância Magnética (IRM) que foram divididas em cortes axiais contendo regiões de 
interesse específicas, dado que na prática clínica as imagens convencionais são imagens a 2D, 
para classificação de doentes com PD, SWEDD e pessoas saudáveis. Para a avaliação do 
classificador calculou-se o Kappa de Coehn e a Característica de Operação do Receptor. Os 
resultados obtidos sugerem que CNN foi capaz de diferenciar DP do grupo de controlo 
(exatidão: 97,4% IRM e 92,4% SPECT) e DP de SWEDD (exatidão: 97.4% IRM e 93.3% 
SPECT) com recurso a informação de imagem dos gânglios da base e mesencéfalo, mas não 
foi capaz de discernir controlos de SWEDD. Deste modo, conclui-se que esta abordagem 
poderá ser útil para auxiliar no diagnóstico de DP no futuro.  
 
Palavras-Chave: Classificação de síndromes parkinsonianos – SWEDD - DaTscanTM – IRM 
– Redes neuronais convolucionais 
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Chapter 1 Introduction 
 
1.1 Motivation  
Parkinsonian Syndromes (PS) are progressive neurodegenerative disorders that mainly affect 
elderly people [1], [2]. PS, also known as Parkinsonism, are chronic movement disorders that 
affect the central nervous system and are characterized by motor symptoms such as 
slow/impairment movement with rigidity and/or tremor [1], [3]. Inside of the group of PS, 
Parkinson’s Disease (PD) is the second neurodegenerative disorder more frequent in the world 
and the commonest PS followed by the Atypical Parkinsonism (AP) [1]. AP includes Multiple 
System Atrophy (MSA), Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration 
(CBD) [1], [3]. About of 75% of PS cases are PD, 5% are PSP and 5% are CBD [4]. 
According to epidemiologic and demographic studies, as world population is increasing as well 
as aging, it is estimated that PS, specially PD, will drastically increase in the following decades 
[1]. According to World Health Organization, PD has an incidence rate of 9.7 to 13.8 per 100,000 
population per year [5] and approximately a prevalence of 1 million people in United States and 
in Western Europe [1]. In Portugal, it is estimated that about 18,000 inhabitants are also suffering 
from this disease [6].  
PS are not only characterized by motor symptoms. Patients may also suffer from mood disorders, 
sleep disturbances, cognitive impairment, urinary incontinence, sexual dysfunction and 
orthostatic hypotension [1], [5]. However, it is important to notice that these features and the 
motor symptoms tend only to be manifested at advanced stages of the diseases [1], [7]. At early 
stages of these diseases, the symptoms are not yet manifested or are very subtle [7]. Besides, when 
features are manifested even at early-onset, they tend to be very similar between PS and other 
movement disorders such as Essential Tremor (ET) [8]. Thus, it still is very difficult to 
differentiate them and have a precise diagnosis [9].  
Currently, there are approaches and scales to diagnose PS based on their clinical features, namely 
the United Kingdom Parkinson’s Disease Society Brain Bank (UKPDSBB) clinical diagnostic 
criteria  [10] and the Hoehn and Yahr Scale [11]. This criteria and scale include motor symptoms 
and a good response to Levodopa, a PD medicine. PD patients have an excellent response to that 
medication unlike AP who present poor response [1]. This medication acts in the affected and 
pathological regions of PS [1].  
Pathologically, PS are characterized by a deficit of dopamine that originates motor disorders. The 
dopamine is produced in the substantia nigra, a structure in the mesencephalon [1] In PS, this 
structure is degenerated faster than normal when compared with elderly people [1].  
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Despite the fact that PS diagnosis remain clinical, medical imaging have been useful for the study 
of neurodegenerative diseases [12–14]. For instance, Magnetic Resonance Imaging (MRI) has 
been used to detect structural changes and distinguish PS and Single-Photon Emission Computed 
Tomography (SPECT) with Dopamine transporter (DaT) imaging has been used to detect the 
referred dopamine degeneration and distinguish PS from other motor diseases. Both techniques 
turn out to be useful in providing neuroimaging biomarkers [1], [12]. In fact, these SPECT images 
led to the discovered of a sub group of patients early diagnosed with PD that presented Scans 
Without Evidence for Dopaminergic Deficit (SWEDD) [12], [13], [15], [16]. These subjects are 
now referred to SWEDD patients. Some studies refer that 10-20% of PD patients are SWEDD 
patients and point out that this may related with misdiagnosis and instead of PD these patients 
may suffer from another motor disorder in which there is no substantia nigra degeneration like 
dystonic tremor [17], [18].  
Usually, DaT SPECT images are interpreted visually by experts but the European Association of 
Nuclear Medicine Neuroimaging Committee recommends that a quantitative analysis should also 
be performed to improve the interpretation [19], which includes the use of Artificial Intelligence 
(AI) techniques [16]. 
AI has recently become an useful tool in the medical field, specially applied in the classification 
and analysis of neuroimaging data [16], [20]–[22] which includes Convolution Neural Networks 
(CNN) which are an useful tool for pattern recognition and visual-classification problems and 
have been used in the study of neurodegenerative disorders [22]–[25]. 
Therefore, distinguishing early stages PS and other movement disorders with similar symptoms 
has become a need and a challenge [26].  An early diagnosis not only reduces the economic health 
care systems costs but also aid in the treatment adjustment since the therapeutics is different for 
each PS and for the SWEDD patients [5]. Moreover, this  will also increase their quality of life 
of patients [5].  
In this study, it is proposed an approach to aid and improve early diagnosis of Parkinson’s Disease 
and SWEED patients based on a CNN framework using 2D MRI and 2D DaT SPECT images 
since the conventional medical images, in clinical practice, are 2D images [27] which are faster 
to acquire than 3D images. 
 
1.2 Goals of the study 
The main goal of this dissertation is to classify MRI and SPECT images of PD, SWEDD and 
healthy subjects using CNN.   
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To achieve this, the following secondary objectives will have to be reached: 
1. Extract MRI and DaT (DaTscanTM in this case) SPECT images of the Parkinson’s 
Progression Markers Initiative (PPMI) database and analyse demographic information 
about the patients, such as age and sex;   
2. Perform MRI and SPECT images pre-processing; 
3. Divide MRI and SPECT images into slices of the axial anatomical view; 
4. Train, validate and test the CNN model.  
With this approach it is intended to aid and to improve the early diagnosis of PD and to understand 
SWEED and PD imaging differences.  
1.3 Dissertation Structure  
This dissertation is comprised by this present chapter, the Theoretical Background chapter, the 
Methodology chapter, the Results chapter, the Discussion chapter and the Conclusions chapter.  
The present chapter, Introduction, briefly introduce some important concepts used in this 
dissertation, contextualized the study and enumerate the objectives. In Chapter 2, Theoretical 
Background, it is explained theorical concepts about PS, MRI and SPECT images and CNN, and 
it is described the state of the art of MRI and SPECT images in the study of PS and CNN 
applications in the medical field as well as other algorithms to classify PS. In Chapter 3, the 
Methodology, the criteria used for the formation of the data set is described as also MRI and 
SPECT images pre-processing steps, CNN architecture and how these were trained, validated and 
tested. In Chapter 4, the results obtained are described in the form of tables and representative 
plots. In Chapter 5, Discussion, the discussion of the results obtained is presented with a brief 
comparison with other studies. In the last Chapter, the conclusion and future work are presented.  
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Chapter 2 Theoretical Background 
 
In this Chapter, the theoretical concepts related with PS, MRI and SPECT DaTscanTM images 
acquisition and CNN architectures is described as the state of the art in the PS field including how 
MRI and SPECT images are used for the study of these diseases and the studies that used CNN 
as tool for PS classification. 
2.1 Parkinsonian Syndromes 
2.1.1 The History of Parkinsonian Syndromes 
PS has been described since early ages. The first texts found go back to ancient China and India, 
between 1000 and 500 B.C.[28], [29]. These documents describe symptoms very similar to those 
in parkinsonism [28], [29]. 
In 1817, PD was set as a neurological syndrome by the physician James Parkinson who observed 
and studied six cases of patients with PD, initially know as Shaking Palsy [30], [31] Parkinson 
described Shaking Palsy patients as having involuntary tremor, decrease of muscular strength and 
tendency to lean forward [30], [31].   In the middle-to-late of 19th century, Jean-Martin Charcot 
and his students could describe clinically this disease and discovered that Shaking Palsy patients 
do not necessarily present tremor as symptom and that these patients were not so weak as 
previously thought, which made them change the name of the disease for Parkinson' Disease [30]. 
In 1895, Richer and Miege gave a very important contribution to the understanding of PD 
progression through the publication of drawings and statues photos that illustrated the disability 
stages of this disease [30], [32], as illustrated by Figure 2.1. 
 
 
 
 
 
 
 
 
Figure 2.1 Drawings of the normal and pathologic erect position. a) Normal men have an erect position. 
Head in the vertical axis, as well as his back b) Parkinsonian patients tend to tilt their heads forward to the 
foot vertical axis. Adapted from Goetz [30]
a) b) 
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A few years later, Brissaud advanced with the possibility that substantia nigra damage could be 
the anatomical cause of PD and Greenfield and Bosanquet reported a full pathological analysis of 
PD as well as Parkinsonism based on brain injuries [30], [33]. Charcot studies also reported that 
PD patients can also present bradykinesia, that is, slow movements, as the responsible cause for 
difficulty in performing ordinary daily activities instead of the tremor or rigidity [30], [32], [34].  
Moreover, this author discovered that some PD patients differed in their symptoms [32], [34]. 
Initially, Charcot aimed to distinguish PD from other neurological diseases such as Multiple 
Sclerosis (MS) [34]. Charcot found that PD patients differ from MS and other diseases by the fact 
that they present rest tremor, rigidity, very soft speech, bradykinesia and a hunched posture [30], 
[32], [34]. He and his students were the first to report the atypical features present by some 
patients. These patients were characterized by an extended posture, a different facial expression 
and no tremor  as shown in Figure 2.2, which are different features from those manifested by PD 
patients [34].  Because of that, the term Parkinson-plus-syndromes or PS has coined [29].  
 
 
 
 
Figure 2.2 Charcot's drawings at his lesson (June 1888) illustrating Parkinsonian Syndromes.  a) Men at left 
has PD and it is characterized by a curved posture. The men on the right has Parkinsonism with an extended 
posture. b) These four drawings illustrate an atypical Parkinson’s Disease case of a Charcot’s patient. This 
patient shows a frightened expression, forehead muscles contracted despite the placid and blank stare of 
PD patients. Adapted from: [34] 
Nowadays, PS include PD, PD with dementia with Lewy Bodies, AP, Secondary Parkinsonism 
and other neurodegenerative diseases such as Huntington’s disease and Alzheimer’s disease with 
parkinsonism [1], [3]. As referred previously AP includes MSA, PSP and CBD and, in its turn, 
Secondary Parkinsonism covers drug-induced, infections and toxins [1]. 
2.1.2 Clinical and pathophysiology of the Parkinsonian Syndromes  
The following lines describes the clinical status and pathology of the PD, MSA, PSP and CBD.  
Patients with PS usually manifests identical motor symptoms such as bradykinesia, tremor and 
rigidity [1], [3]. These symptoms are associated with damage in structures responsible for motor 
control in the brain, namely, basal ganglia., and these injuries depend on the type of PS that the 
patient has. This damage in the basal ganglia is associated to dopaminergic neurons degeneration 
and consequently the dopamine deficit in specific brain areas [1], [3], [35]. 
Since PS are neurodegenerative diseases it is important to briefly explain some concepts related 
a) b) 
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with brain structures before the explanation of PS pathophysiology itself. The brain is comprised 
by cells called neurons which are small structures that communicate to each other by transmitting 
stimulus and sensations from the environment and command the body to respond to this stimulus, 
[36]–[38], as shown on Figure 2.3 a). These cells communicate by sending the stimulus through 
a contact zone between neurons called synapse [37], [38]. The synapses are divided into two 
types, electric synapses and chemical synapses. The last ones are the commonest in the brain. In 
the electric synapses, the neurons terminals are physically connected by protein channels that 
enable the passage of the electric impulse. In the chemical synapse the impulse electric pass from 
one neuron to another through chemical substances called neurotransmitters. The axon terminal 
from the transmitter neuron has a terminal button that contains vesicles with neurotransmitters 
inside. These vesicles merge with the pre-synaptic membrane and the neurotransmitters are 
released in the synaptic gap. Then, these neurotransmitters bind to specific receptors located in 
the postsynaptic membrane in dendrites’ terminations of the receptor neuron. Thus, the electric 
impulse is propagated through the neuron [37], [38], as illustrated on Figure_2.3 b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Neuron structure and chemical synaptic. a) Normal structure of a neuron b) Chemical synaptic. 
Neurotransmitters are messengers that send the information from one neuron to other. Adapted from [38] 
Regarding PD, this disease is strictly related with neurons degeneration and deficit of dopamine, 
an important neurotransmitter related with motor control among other functions. [1]   
The pathological hallmarks of PD are degeneration of the dopaminergic neurons located at the 
substantia nigra, as shown in Figure 2.4, reduction of the striatal dopamine, and abnormal 
a) 
b) 
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accumulation of protein aggregates, known as Lewy bodies, in injured cells of the substantia 
nigra, [1], [39]. These pathological features are responsible for the motor symptoms and signs 
that PD patients present. For instance, the neurodegeneration that occurs in substantia nigra 
affects all the basal ganglia cycle which, together with thalamus, are responsible for motor control 
functions. Once the cycle is affected, the information that reaches the motor cortex is not 
regulated, which leads to changes in movement [1], [40]. 
 
 
 
Figure 2.4  Substantia nigra a) Substantia nigra of a healthy subject, the presence of the neuromelanin 
dopaminergic neurons are visible in the image due to its characteristic black color. b) Substantia nigra from 
a PD patient, wherein the absence of dopaminergic neurons is visible. Adapted from: [12] 
In healthy people, the basal ganglia system controls the motor system and avoid involuntary 
movements. In addition to motor control, basal ganglia are also responsible for cognitive functions 
and behaviour control [1]. The process of motor control is possible due to connections between 
basal ganglia structures along with the thalamus and the cortex. This junction responsible for 
motor control is called the Basal Ganglia model or Cortico-Basal Ganglia-Thalamo-Cortical 
(CBGTC) loop. The basal ganglia are comprised by two primary inputs, striatum (caudate nucleus 
and putamen) and subthalamic nucleus (STN), by two primary outputs, internal segment globulus 
pallidus (GPi) and substantia nigra pars reticulata (SNr) and by two intrinsic structures, external 
segment globulus pallidus (GPe) and substantia nigra pars compacta (SNc), as shown in Figure 
2.5. [1], [41], [42]  
Figure 2.5 Basal ganglia structures. a) The color structures indicate the anatomical position in the brain of 
the basal ganglia, putamen and caudate nucleus b) Names of the structures of the basal ganglia with striatum 
(putamen and caudate nucleus) and thalamus. Adapted from: [41] 
a) b) 
a) 
 
b) 
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The basal ganglia model is organized into two pathways: the direct pathway and indirect pathway 
that act together to control the body movements. The direct pathway occurs when the motor cortex 
is stimulated, for instance, to initiate or perform a movement. In its turn, the indirect pathway 
stops a movement or prevent the body from doing involuntary movements [1], [42]. 
In the direct pathway, the motor cortex sends an excitatory stimulus to the striatum and the STN. 
In its turn, the striatum sends an inhibitory stimulus to GPi and SNr, whereas STN sends an 
excitatory stimulus to GPi, SNc, and SNr. SNc modulates neuronal firing and equilibrates the 
basal ganglia cycle by transmitting and increasing dopamine neurotransmitters to the striatum 
receptors called D1, which will raise the activity in the striatum cells. Thus, the striatum increases 
the inhibitory stimulus sent to the GPi. In its turn, GPi reduce its activity and does not send any 
signal to the Ventral Lateral nucleus (VLN) of thalamus which allows it to send excitatory 
stimulus to the motor cortex and spinal cord to allow motor functions [40], [42].  
In the indirect pathway, the striatum and STN also receive the excitatory stimulus from the cortex. 
Then, the striatum sends an inhibitory stimulus to the GPe and the STN to the SNc. The SNc will 
increase the dopamine in the striatum in the D2 receptors which lead to a decrease of an inhibitory 
impulse to the GPi. Consequently, GPi and SNr can send inhibitory signals to VLN. Then, the 
activity of the motor cortex is decreased, and no movement is executed since VLN cells get the 
stimulus of inhibition. All this process is illustrated in Figure 2.6 [40], [42]. 
Figure 2.6  Comparison of the CBGTC from a heathy person and PD patient. The red arrows represent the 
excitatory stimulus, the blue arrows represent the inhibitory stimulus and the green illustrate dopaminergic 
neurons. These neurons originate an excitatory stimulus if they are bounded to the D1 receptor or inhibitory 
if they are bounded to the D2 receptor. In a) there is represented the normal CBGTC. b) illustrates the 
CBGTC of a subject with PD. In this case, the dashed green lines represent the dopamine deficit which 
causes an increase of the inhibitory stimulus in the GPe (blue arrow in bold) which lead to motor symptoms. 
Adapted from:[1] 
In PD, the basal ganglia suffer dopaminergic neurons degeneration in the SNc which become 
pathologically degenerated and leads to the dopamine deficit in the striatum. Consequently, there 
is an increase of neurons fire in SNr and GPi. These two structures give rises to excessive 
inhibition of the thalamus and consequently an extreme reduction of the activity in the motor 
a) b) 
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cortex that originates the parkinsonian features [1], [40]. These motor symptoms arise when 
approximately 50% of the substantia nigra has already degenerated [43]. 
Besides the degeneration of the dopaminergic neurons and the reduction of dopamine in the 
system, post-mortem studies show an evidence of an abnormal aggregated of specific proteins in 
the injured neurons, known as Lewy Bodies [1]. These structures have a spherical form and are 
filamentous inclusions formed by presynaptic protein alpha-synuclein that combines with other 
components present in the neurons [1], [44], [45]. The reason why this agglomerated forms and 
why the protein α-synuclein pull out of its binding sites in the presynaptic axon terminal still 
unknown [44], [45]. 
To summarize, clinical PD is based on several features that include motor and non-motor 
symptoms [1]. Non-motor symptoms such as depression and dementia tend to manifest in the last 
stages of the disease,  as shown in Table 2.1[1]. 
Table 2.1 Clinical features of Parkinson’s disease. This table introduces the clinical features that PD patients 
manifest through the course of the disease. Anosmia is usually the onset of PD. Motor signals tend to 
manifest at advanced stages since they are related with degeneration of the SNc.  Adapted from [1] 
 
Concerning PD treatment, since the 1960s that this therapy includes a medicine called levodopa 
[1], [46]. Since artificial dopamine does not cross the blood-brain barrier, a barrier that protects 
the brain from strange particles and molecules, scientists create levodopa (commonly known as 
L-DOPA) which is a dopamine precursor. Levodopa is capable of penetrating in the brain and 
then is converted into dopamine [1], [46]. However, Levodopa has some side effects, namely, 
nausea, vomiting, and orthostatic hypotension. Moreover, at advanced stages of this illness and 
with a long-term of taking this medicine, PD patients may manifest excessive involuntary muscle 
Clinical features of PD 
Principal Motor Features Other Motor Features Non-Motor Features 
Bradykinesia (2) 
Rest tremor (2) 
Rigidity 
Gait impairment 
Reduced eye blinking 
Soft voice 
Dysphagia 
Masked facies (hypomimia) 
Anosmia (1) 
Sensory disturbances (e.g., 
pain) 
Mood disorders (e.g., 
depression) (3) 
Sleep disturbances (1) 
Autonomic disturbances 
Cognitive impairment (3) 
(1) E.g. of symptoms/signals that manifests are early stages of PD  
(2) E.g. of symptoms/signals that manifests at middle stages of PD 
(3) E.g. of Symptoms/signals that manifests at advanced stages of PD 
2.1 Parkinsonian Syndromes 
 
10 
 
contractions, which may originate abnormal postures and diphasic dyskinesias [1], [47], [48]. 
These symptoms appear due to chronic administration of the Levadopa, which causes fluctuations 
as a decrease of its effect in the organism [1], [49]. 
Concerning AP and Secondary Parkinsonism, these syndromes are also neurodegenerative 
diseases but differ from PD since the damage of the neurons can also occur in the striatum and 
globus pallidus [1]. Besides, these types of parkinsonism do not present Lewy bodies in the 
neurons of the SNc. [1]. In the beginning, AP and Secondary Parkinsonism patients present a 
good response to levodopa, but along the disease progression of the disease, the subjects starts to 
present a poor response [1]. 
More specifically, MSA can be parkinsonism (MSA-p) or cerebellar (MSA-c) predominant 
according to their main symptoms [1]. Clinically, MSA-patients can also present autonomic 
features because the autonomic nervous system is also affected [1], [50], [51]. The autonomic 
nervous system innervates all the organs of the body and is responsible for maintaining the 
homeostasis of the body by controlling blood pressure and heart rate [52], [53]. One example of 
autonomic dysfunctions that these patients manifest is orthostatic hypotension which can cause 
symptoms such as erectile dysfunction in males or urinary problems [50]. According to Harrison’s 
Principles of Internal Medicine, “Pathologically, MSA is characterized by degeneration of the 
SNc, striatum, cerebellum, and inferior olivary nuclei coupled with characteristic glial 
cytoplasmic inclusions (GCIs) that stain for α-synuclein” [1]. 
Regarding PSP, also known as Steele–Richardson–Olszewski syndrome, is pathologically 
characterized by loss of neurons in the striatum, SNc, subthalamic nucleus, midline thalamic 
nuclei and abnormal inclusions in the tau protein [1], [54]. PSP symptoms are restricted eye 
movements, gait impairment that leads to falls, and cognitive dysfunctions. These symptoms 
occur at different stages since it affects different nuclei [54]–[56]. Unfortunately, PSP develops 
at a very fast pace. The first symptoms usually manifest at the mid-60s with a faster progression 
that leads to death in 7 years on average [57]. Until now, the advanced age it the only risk factor 
of this disease [57]. 
CBD is a rare condition that affects the cerebral cortex and the basal ganglia by loss and atrophy 
of the neurons [1], [58]. The progression of the disease is slow and occurs during 6 to 8 years [58] 
and causes dystonic contractions and sensory disturbances. [1] 
Overall, there are specific symptoms for each PS. For instance, the absence of tremor, early 
speech, and gait impairment suggests a possible Atypical Parkinsonism; manifestations of 
hallucinations and dementia as the first signal as well as Parkinsonian features indicate a 
Dementia with Lewy bodies; diplopia, impaired down gaze may suggest PSP; predominant 
orthostatic hypotension may indicate an MSA [1]. 
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It is important to notice that the causes of Parkinsonian Syndromes are still unknown. [1], [3], 
[57] Early onset of PD before the age of 40 may indicate a genetic form of PD caused by genetic 
factors including gene mutations, especially mutation of the alpha-synuclein gene. However, most 
of the cases, approximately 85–90%, the factors that induce PD is not known yet. Some studies 
correlate environmental and lifestyle factors with idiopathic PD, i.e., Parkinson with an unknown 
cause [1], [59]. For instance, Hwang studied the possibility of the oxidative stress due to 
neuroinflammation being related to the SNc degeneration [60]. In 2003, H. Braak et al. advanced 
with the hypothesis that the protein alpha-synuclein arises at the gastrointestinal system and then 
spreads to the brain through the vagus nerve [39]. However, this lacks more studies and evidence 
to prove that this process may happen [61]. 
2.2 De novo PD patients 
De novo PD patients is a clinical expression to define a group of PD-patients that either does not 
receive any Levodopa treatment or were recently diagnosed as having Parkinson’s Disease [62].  
2.3 Non-Parkinson’s disease tremor: Essential Tremor 
Essential Tremor (ET) is a common movement disorder, monosymptomatic, of unknown cause 
and sometimes misdiagnosed with neurodegenerative diseases such as PS [1], [63], [64]. ET 
patients manifest symmetric high-frequency tremor (6–10 Hz) and voice or head tremor but show 
no evidence of changes in the dopamine in the dopamine system [1], [7], [63]. 
2.4 State-of-art: diagnosis of Parkinsonian Syndromes 
Over the years, several authors have proposed methods for PS diagnosis by elaborating scales that 
enumerate characteristics and signals for each illness [65]. In this study, only the most common 
were described. 
In 1967, Hohen and Yhar studied the progression and morbidity of patients with parkinsonism 
and developed a scale of PD progression, the Hoehn and Yhar (HY) Scale, which are nowadays 
accepted and internationally used [11]. HY Scale enumerates PD stages by describing symptoms 
that occur at each level. This scale was created to be used in follow-up progression of PD before, 
during and after treatment and consequently to promote a better evaluation of the therapy [11]. 
The scale comprises five stages that are based on the symptoms and the clinical degree of 
disability of the patients. In Table 2.2, the HY Scale is entirely reproduced without alterations. In 
the 1990s, HY Scale was slightly modified and it was added two intermediary levels: Stage 1.5: 
“Unilateral and axial involvement ” and Stage 2.5: “Mild bilateral disease with recovery on pull 
test “ [66]. This modified HY Scale emerged due to HY scale limitations, namely the fact that 
some patients may manifest the same symptoms at different stages [66]. Despite this, HY scale 
still be used for medical evaluation worldwide for PD symptom stage evaluation. [66] 
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Table 2.2 - Hoehn and Yahr Scale. This scale created in 1967 represents 5 stages of Parkinson´s Disease. 
Stages I, II and III represent the less levels of disability whereas Stage IV and V represent severe levels of 
disability. Entirely obtained from [11]  
Hoehn and Yahr Scale  
Stage I “Unilateral involvement only, usually with minimal or no functional 
impairment.”[11] 
Stage II “Bilateral or midline involvement, without impairment of balance.” [11] 
Stage III “First sign of impaired righting reflexes. This is evident by unsteadiness as the 
patient turns or is demonstrated when he is pushed from standing equilibrium with 
the feet together and eyes closed. Functionally the patient is somewhat restricted 
in his activities but may have some work potential depending upon the type of 
employment. Patients are physically capable of leading independent lives, and 
their disability is mild to moderate.”[11] 
Stage IV “Fully developed, severely disabling disease; the patient is still able to walk and 
stand unassisted but is markedly incapacitated.”[11] 
Stage V “Confinement to bed or wheelchair unless aided.”[11] 
 
In 2003, H. Braak et al. studied 41 cases of subjects clinically diagnoses as PD. Based on the 
clinical and pathological analysis of the patients, Braak et al. present a study that describes six 
stages of PD progression and the distinction of the initial, intermediate and final phases of the 
disease [39]. These stages were formed taking into account the presence of Lewy bodies as well 
all pathologies and symptoms manifested by patients and related studies. The Braak stages are 
following described. 
• Stages 1 and 2: 
In this phase of the illness, PD patients present non-motor symptoms that precede motor 
symptoms [67]. According to the literature, PD-patients tend to suffer from an impaired sense 
of smell that arises before the motor symptoms [68], [69]. Thus,  one study points out that an 
early exam of the olfactory performance when this symptom rise could evidence a possible 
early PD diagnosis [70]. Besides smell impairment,  PD patients may also manifest autonomic 
dysfunctions and Idiopathic Rapid Eye Movement Sleep Behaviour Disorder,  during the 
early stage of the disease [39], [71].  
• Stages 3 and 4: 
According to Braak et al., the pathology of stage 3 and 4 given by the injuries, i.e., the 
dopaminergic neurons start to get injured or degenerated which leads to the appearance of 
motor symptoms[39]. In stage 4, the damage in the olfactory nucleus is getting more severe. 
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It also in these two stages, 3 and 4, that Lowy bodies get formed and present in the lesioned 
neurons [39]. 
• Stages 5 and 6: 
These two stages are the most severe in this disease [39]. In stage five, the pathology reaches 
areas in the neocortex and prefrontal neocortex. In stage six, the neurodegeneration in the 
SNc is evident, and the disease develops affecting deeper regions such as the sensory and 
motor areas [39]. 
In 2007, Goetz et al. presents a revision of the Unified Parkinson's Disease Rating Scale 
(UPDRS), one of the most used scales for the clinical study of PD [72]. The UPDRS scale is a 
questionnaire with several questions divided into four parts concerning disabilities and 
impairments to classify PD severity [73]. This revision, also known as Movement Disorder 
Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), 
adds a new section that incorporates nonmotor features of PD [72] and allows the identification 
of the PD problems that a PD-patient may develop [72], [73]. Part I - Nonmotor Aspects of 
Experiences of Daily Living includes features of dopamine dysregulation syndrome, urinary 
problems, and cognitive impairment.; Part II - Motor Experiences of Daily Living contains 
walking and balance, tremor impact on activities and eating tasks; Part III - Motor Examination 
includes speech, Hand movements, gait, Postural tremor of hands, rest tremor amplitude and Part 
IV: Motor Complications covers dyskinesias (involuntary muscle movements) and motor 
fluctuations [1], [72]- 
Nowadays, the most used criteria are the UKPSBC [74]. With 80% of accuracy, UKPSBC were 
created by the analyses of 100 patients with Idiopathic Parkinson’s Disease [10], [65]. This study 
found out that some of these patients were misdiagnosed as PD, instead of having this disease, 
they suffer from some other PS or Alzheimer’s Disease. UKPSBC is formed by three steps. The 
first step enumerates and characterizes motor symptoms of PS such as bradykinesia or rest tremor, 
as shown in Figure_2.7. The second step lists pathologies that are not present at PS namely severe 
dementia at early ages and negative response to PD medication, levodopa. The last step describes 
signs and characteristics that the patient must have to be diagnosed with PD and includes good 
response to PD medication Levodopa and rest tremor presence. In this step, the diagnosis is valid 
when the patient presents at least three attributes [10]. 
To study mild cognitive impairment in neurologic diseases it is was develop a 10-minute cognitive 
screening tool called The Montreal Cognitive Assessment (MoCA) [75]. This test analyses 
cognitive domains such as attention and conceptual thinking [76]. 
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  Figure 2.7 United Kingdom Parkinson’s Disease Society Brain criteria. Elaborated by [77] 
For AP such as MSA, PSP and CBD several authors proposed clinical diagnostic criteria based 
on post-mortem studies and specific features [65]. In 1994, Quinn proposed a diagnostic criteria 
based on specific features of MSA: Possible diagnostic of  MSA includes sporadic adult-onset 
and poor response to levodopa, and Probable diagnostic of  MSA includes Possible diagnostic of  
MSA and severe autonomic failure [78]. For PSP, Lees describes clinical features that differ PSP 
from PD, namely the type of response for Levodopa (poor or excellent) and differences between 
balance, speech and facial appearance in the two illness[56]. Regarding CBD, there are no 
diagnostic criteria that were validated so far [65], [79].   
The first diagnoses of Parkinsonian syndromes were merely based on visual signs and symptoms 
[1], [30] However, post-mortem studies found a 24% of misdiagnosis [1]. Thus, several clinically 
criteria such as those mention above have been created. Besides clinical diagnosis, it is also 
essential to study the pathology of the disease, through methods that may aid in the diagnosis. 
[80]. Due to this need, medical imaging in Parkinsonian syndromes has emerged to show 
anatomical and functional changes related to PD pathologies [1]. 
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2.5 Medical Imaging in Parkinsonian Syndromes 
Through the years, medical imaging techniques have been aiding physicians and researchers in 
the study and understanding of PS [1], [25], [26]. Nowadays, the scientific community use several 
techniques such as MRI including Diffusion Tensor Imaging (DTI) SPECT Positron-emission 
tomography (PET). This study only focuses on MRI and SPECT [81]. 
2.5.1 Magnetic Resonance Imaging 
In the following lines, the physics behind MRI will be briefly explained. MRI is an anatomical 
image that represents the structure and the tissues, in this case, of the brain. 
MRI is an imaging modality based on physical principles of the atomic nuclei [82]. These nuclei 
have magnetic properties that can be translated into in a signal that is captured by coils. This 
signal allows a formation of an image [83]. Usually, hydrogen is the most nuclei used in MRI 
because it is the most abundant element in the human body, being present in water and lipids [82], 
[83] The physics behind the formation of this signal relies on the magnetic moment and angular 
momentum of the nuclei, the hydrogen proton [82]. The magnetic moment gives the magnetic 
strength and the orientation of the moving electric charge when this charge is interacting with an 
external magnetic field. When no external influences are applied such as magnetic and electric 
fields, the proton spins about itself, i.e., rotate around itself [82]. The hydrogen proton is positively 
charged and has that spinning movement which allow the production of an electric current that 
creates magnetic movement. The angular moment is then created due to the mass of the rotating 
proton multiplied by its angular velocity. [82]  
In MRI a constant magnetic field is applied to the body, in this case, the head, to gives a precession 
movement and a specific orientation to protons that were previous randomly orientated as 
illustrated in Figure 2.8 [82], [83]. These protons can be orientated parallel or antiparallel to the 
constant magnetic field applied. The parallel protons have lower energy while antiparallel protons 
have higher energy level.  
 
 
 
 
Figure 2.8 Proton orientation in MRI. a) Protons randomly oriented in free space b) Protons oriented 
according to the magnetic field. The protons which are aligned with the magnetic field are represent in blue. 
The process movement is the same as the gyroscopic motion but in this case the proton process 
due to the constant magnetic field and its orientation, as shown in Figure 2.9. 
a) b) 
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Figure 2.9  Precession Movement. The proton rotates around the direction of constant magnetic field.  
The MRI techniques measure the magnetization of all spins in the free space. The magnetization 
can be represented by one vector with two components, the longitudinal and the transverse [82]. 
The longitudinal component has the same direction as the constant magnetic field while the 
transverse component is perpendicular and has the zero value. When all the protons are aligned 
with the magnetic field, parallel or antiparallel, one pulse sequence perpendicular to the magnetic 
field is applied to the system. The pulse sequence is characterized by radiofrequency (RF) pulses 
and gradient pulses, which control timings and other parameters that allow the acquisition of the 
image [82], [83]. This pulse changes the amplitude of the longitudinal and transversal 
magnetization, by changing the magnetization of the longitudinal axis to the transverse plane. 
During the pulse, all protons are in the transverse plane, rotating with the same phase [82]. 
After pulse application, the magnetization tends to return to the equilibrium position and occurs 
transverse relaxation and longitudinal relaxation. The transverse relaxation also known as spin-
lattice relaxation is the decrease of net magnetization because of the loss of spins coherence of 
the protons [82]. In its turn, the longitudinal relaxation or spin-spin relaxation is the recuperation 
of the net magnetization along the horizontal axis because the protons tend to return to the 
equilibrium state, parallel to the magnetic field [82]. In MRI signal, these events are traduced by 
two relaxation times T2 and T1. In MRI signal, these events are traduced by two relaxation times 
T2 and T1. T2 is a time constant that represents the exponential decay of the net magnetization in 
the transverse wherein protons spin at different phases, as shown in Figure 2.10 [82]. 
 
 
 
Figure 2.10 Illustration of the T2 decay. During the pulse sequence the spins are perfect aligned. Once the 
pulse sequence is turn off, protons lose their phase coherence and gain different orientations. Adapted from 
[85]  
The recovery phase of the longitudinal magnetization is given by the time constant T1 which 
indicates the time that protons took to return to the equilibrium state before the excitation caused 
by the radiofrequency pulse, as illustrated in Figure 2.11 [82]. 
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Figure 2.11 Illustration of T1 recovery. The spins, initially in the transverse plan, return to the initial 
position and orientation in the longitudinal axis, represented as z in the image. Adapted from [82]  
During the image acquisition, the constant magnetic field is always turn on and may have slight 
differences in its intensity, which originate spatial inhomogeneities since the spins will be 
processing at different speeds. [82]. This event is translated by the time constant T2*. T2* reflects 
the quickly lost of coherence between the spins due to the spatial inhomogeneities [82]. 
T1 and T2 values depend on the proton density of the tissues. T1 is always bigger than T2.  Tissues 
with a high number of hydrogen protons have long  t1, e.g., fluids have longer T1 than T2 [83]. 
The contrast of the MRI images is related to T1 and T2 parameters and Proton density [82], [83]. 
Each constant time gives different structure contrast to each image. Thus, the images can be T1-
Weighted (T1-W), T2-Weighted (T2-W) and Proton Density weighted. These images are 
produced using Spin-Echo (SE) or Gradient-Echo (GE) which are pulse sequences. These pulse 
sequences are related with two concepts, Repetition Time (TR) and Echo Time (TE), respectively. 
The contrast in MRI is possible due to variations in TR and TE [83]. The SE sequence comprises 
an echo with two RF pulses. In its turn, the GE is formed by one RF pulse followed by one 
gradient that creates the echo. In both sequences, the echo measures the intensity of the signal. 
The function of the gradient is used to accelerates spins dephasing [82]. 
T1-W images give information about the RT of each tissue and are characterized by an 
intermediate TR and a short TE. These images are brighter in voxels containing tissues with short 
T1 because the spins in these tissues are the first to recovery to longitudinal magnetization and 
darker in voxels comprising tissues with long T1. For instance, the white matter is very bright, 
the water-based tissues such as grey matter are mid-grey and the fluids are dark. Thus, T1-W 
images shows the boundaries between the tissues and fat-based tissues [83]. 
T2-W have long T1 and intermediate TE. In this cases, the grey matter and fluids get bright and 
the fat-based tissues get dark since the spins had totally recovered [82]. PD Weighted images 
allows to distinguish fluid from cartilage [83].  
T1 
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2.5.2 State-of-the-Art: T1-Weighted and T2-Weighted images in PS 
MRI is usually used as routine to differentiate symptomatic parkinsonism from controls and to 
detect if there are any cerebrovascular damage causing the PS features [14]. 
On the one hand, according to the literature, anatomical changes in early-PD are very subtle in 
structural MRI [81], [84]. For instance, T1-W images present poor contrast in regions of interest 
areas such as STN and GP which difficult the detection of pathological anatomic findings [81], 
[84], [85]. 
On the other hand, the literature also describes MRI findings in structural alterations in PD brains. 
Due to the high quantity of iron present in these structures, the T1 value is short and consequently 
T2-W and T2*-Weighted images allow the detection of changes in structures like STN and 
GP[85].  Moreover, a study with 27 individuals with PD that filled Unified Parkinson's Disease 
Rating Scale and HY scale, pointed out for a reduction of 11% putamen in volume and 8% in 
caudate volume in PD when used a high-resolution 3T structural T1-W images when compared 
with control group. Nevertheless, this study also indicated that it is still unclear the relationship 
between the volume reduction and the dopamine deficit. [86]  
Concerning SNc degeneration in PD, some studies report no evidence of volumetric changes in 
SNc of patients [87], [88]. Minate and colleagues found alterations in the SN of PD patients and 
in T1 value in comparison with the control group. However, the authors conclude that these 
differences in SN of PD patients were also influenced by the midbrain size variability for each 
subject [89]. 
According to the literature, increasing the magnetic field in MRI image acquisition may improve 
structural image quality. Kwon et al. use a 7T magnetic field to acquire T2*-weighted MRI 
images of the SN from 10 PD-patients and 10 control subjects. The authors report that the shape 
of the substantia nigra of PD patients differs from Control individuals. Moreover, they also 
identified an increase of the hypointensity of the MRI signal due to a rise in the volume of the SN 
in PD-Patients. The increase of the SN shape is related to high concentrations of iron in PD-
patients, unlike Control subjects which are translated in variations in T2*-weighted MRI signal 
[90]. 
To aid in the detection of structural changes in MRI some techniques have been used, such as 
Voxel-Based Morphometry (VBM). VBM is an MRI technique that allows the analysis of focal 
brain anatomic differences between healthy and patients subjects. VBM uses image processing 
methods such as spatial normalization and segmentation into grey matter, white matter, and 
Cerebrospinal fluid[84], [91]. Using VBM, Burton et al. analyzed T1-W MRI scans from 26 PD-
patients and 26 PD-patients with dementia with the aim to investigate brain volume loss. The 
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study reported that PD-patients presented a reduction of grey matter volume in the frontal lobe 
comparatively to the control group. Regarding PD-patients with dementia, a loss of volume in the 
grey matter of the temporal lobe was found [92]. Other studies with PD patients identified reduced 
grey matter in the right side of the hippocampus and in the left superior temporal gyri, loss of 
volume in the olfactory bulb and volume reduction in grey matter in brain areas related with the 
olfactory system such as inner olfactory cortex and amygdala [93], [94]. The authors conclude 
the volume changes in the olfactory system agrees with the stages hypothesis of Braak. [39], [93]. 
Moreover, one study that used volumetric analysis and segmentation applied to T1-W images of 
PD patients reported volume reduction of the bilateral putamen in comparison with the control 
group [95] and Tinaz et all. applied an automated reconstruction method to T1-W images of PD-
patients and found a reduction volume of the striatum [96]. These findings are related with PD 
pathology and motor symptoms.[1] However, one study that also used T1-W images as well, 
reported mean striatal, cerebellar and brainstem volumes remain normal in comparison with 
control [97].   
Even with these findings, MRI is mostly used to distinguishing atypical syndromes from 
Parkinson's disease due to limited and subtle changes in early-PD brain structures. Nevertheless, 
new approaches to MRI pointed that this medical imaging technique may help in the 
discrimination of nigral degeneration and its progression. [98]  
In Atypical Parkinsonism, MRI has been used to detect changes in PSP, MSA and CBD [99]. 
According to the literature, the most affected areas in these syndromes are basal ganglia, 
brainstem, cortex and cerebellum. The atrophy and changes in these regions originate alterations 
in MRI signal relatively to healthy subjects and PD-patients. [100], [101] The Table 2.3 
summarize the some of the findings achieved so far and present the in literature. [13], [99]  
To sum up, Meijer et al. analysed several studies and proposed that MRI should be a tool to aid 
in PS diagnosis [14]. According to them, T1-Weighted may be used to detect brain atrophy and 
tissue loss but have some limitations, namely, poor contrast in some areas due to low sensitivity 
to signal intensities changes. Regarding T2-Weighted images, those are useful to detect changes 
in the basal ganglia which are detected by signal intensity changes in MRI [14].  
.  
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Table 2.3 Findings in structural MRI in PS 
AP MRI findings Reference 
MSA 
- No alteration in the Olfactory system  
- Atrophy in putamen (also known as putaminal rim sign)  
- Hypointensities in T2-weighted images  
- Atrophy in putamen of MSA subjects differ from PD-patients 
 
Chen et al. [93] 
Yekhlef et al. [102] 
 
Sako et al. [103] 
PSP 
- Volumetric reductions in brain-stem, midbrain and frontal grey 
matter 
- T2-weighted images hyperintensity in the midbrain  
- Midbrain atrophy, known as Hummingbird sign 
- Midbrain tegmentum atrophy known as morning glory sign 
 
Gröschel et al.  [104] 
 
Massey et al. [105] 
CBD 
- Cortical atrophy, lateral ventricle dilatation and mindbrain atrophy 
- Atrophy of parietal cortex and corpus callosum 
 
Yekhlef et al. [102] 
Gröschel et al. [104] 
PD 
- Volume reduction in caudate 
- Volume reduction in putamen 
 
- Differences in substantia nigra shape 
- Volume reduction in the grey matter of the frontal lobe 
- Reduced grey matter in Hippocampus, temporal lobe and olfactory 
bolb  
- Loss of volume in areas of the olfactory system  
Pitcher et al.  [86] 
Pitcher et al.. [86], 
Geng et al. [95] 
Kwon et al. [90] 
Burton et al. [92] 
Chen et al.[93], 
Summerfield et al. 
[94] 
 
2.5.3 Single-Photon Emission Computed Tomography in Parkinsonian Syndromes 
In the literature, some studies have shown that SPECT imaging can be useful to improve PS 
diagnosis criteria, especially when there is the hypothesis of PS diagnosis [15], [80]. In the 
following subchapter, it is described SPECT concepts and how related they are with Parkinsonian 
Syndromes.  
SPECT is a functional nuclear imaging technique. Functional images allow the study and the 
understanding of physiological activities, such as metabolism and blood flow, that occur within 
organs and tissues [13], [106]. 
SPECT images are obtained using radiopharmaceuticals comprise by radioligands that are 
injected in the patient. Once injected, these substances spread in different internal tissues or 
organs and the radioligands bind to specific molecules presented in those tissues and organs. This 
binding originates a reaction that causes gamma rays emission, photons. These photons are 
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capture by radiation detectors, called collimators [106]. The imaged is formed by the acquisition 
of these gamma rays from different views to guarantee that the distribution of radiation in the 
three-dimensional perspective of the body is detected. Then, using imaging reconstructions 
techniques the imaged is formed [106]. 
In this work, SPECT images are obtained from the brain to detect dopaminergic changes. In this 
case, the radiopharmaceuticals usually used are cocaine analogues [84]. These nuclear medicine 
tracers are used for the analysis of a specific brain function or brain pathology, namely the 
dopaminergic function, in which this injected substance binds to dopamine transporters or 
dopamine D2 receptors [84]. The radioactivity dose given to patients is stipulated taking into 
account safety rules [106].  
2.5.4 Dopamine transporter SPECT  
One type of SPECT imaging is DaT SPECT imaging, usually used to differentiate PS and other 
motor diseases such as ET [13].  DaT is a transporter protein located in the presynaptic membrane 
of the striatum that mediates the reuptake of the free dopamine within synaptic gap [107]. DaT 
SPECT exam allows to find out dysfunctions in the dopamine transporter [13], [80]. One of the 
radiopharmaceuticals used in the DaT SPECT imaging for PS is an active substance called 
ioflupane (123I). When injected in the body through the bloodstream, the ioflupane accumulates 
in the dopamine transporters of the striatum. In patients with parkinsonism, there are 
dopaminergic neurons degenerated and consequently less DaT. Thus, the concentration of the 
radioligand is less in the striatum in comparison with a healthy person. This reduction is visible 
on the scan [108]. Factors such as sex and age usually influence DaT density in healthy and 
pathologically subjects. For instance, aging is related with a reduction of DaT in the striatum of 
healthy subjects. However, this reduction is not so strong and evident as the loss in PD-patients 
[109]. Female subjects, healthy or PD-patients, differ slightly from male healthy or PD-patients 
by presenting a higher concentration of DaT [110], [111]. 
To obtain SPECT images it also used radiotracers like 123I-iodobenzamide (123I-IBZM) and 123I-
iodolisuride (123I-IBF)  for the detection of dopamine D2 receptor to obtain information about the 
density of postsynaptic neuronal loss [13].  
2.5.5 PD patients with Scans Without Evidence of Dopaminergic Deficit, SWEDD 
In the literature, drug trails and studies that had used DaT SPECT images to analyse PD-patients 
reported that a few early-PD patients presented normal DaTscan [112]–[114]. For instance, in a 
study with 62 patients with clinical features of parkinsonism and tremor disorders, it was acquired 
DaT SPECT images from all the individuals. Within the participants, 38 fulfilled UK Brain Bank 
step 1 PD criteria and 24 failed standard Parkinson's disease and essential tremor criteria. The 
2.5 Medical Imaging in Parkinsonian Syndromes 
 
22 
 
results obtained showed that 14 of 24 subjects that do not fill in specific criteria had normal scans 
and 5 of 28 patients that were classified as PD had a normal scan [113]. These PD-patients that 
presented a normal scan which indicates that there is no dopaminergic deficit are now called 
SWEDD patients [15].  
Moreover, follow-up studies using DaT SPECT images show that approximately 10% of the cases 
clinically diagnosed as early PD had SWEDD [18] and that those patients tend to have a normal 
DaT SPECT along disease progression [18], [115].  
However, some findings corroborate the fact that patients with SWEDD may have been 
misdiagnosis as PD-patients [116]. On the one hand, there are strong evidence that at early-PD 
stages, when the symptoms first appear, 80 % of striatal dopamine and 50 % of nigral dopamine 
cells are already lost. This reduction can be detect by a DaT SPECT exam which results in an 
abnormal scan. [43], [84], [117] On the other hand, recent studies found that SWEDDs patients 
had normal olfaction score unlike PD patients [17] and present different structural connectivity 
[118]. 
Clinically, SWEDD’s patients can be divided into two categories: tremor dominant or non-tremor 
dominant. Within the causes of tremor dominant SWEDD type are dystonic tremors [15], [18], 
[119] and the causes behind non-tremor dominant SWEDD type are related with Vascular 
Parkinsonism or Huntington’s disease [15]. Besides the evidence of the dopamine neurons 
without degeneration, SWEDD patients are also characterized by the fact that the glucose 
metabolic patterns are also normal [120]. Regarding the response of SWEDD patients to L-Dopa, 
in the literature this is dubious. [112]  
2.5.6 Diagnosis of Parkinsonian Syndromes with DAT-SPECT 
The literature suggests that DaT SPECT scans can be an asset to improve diagnostic accuracy as 
well as to aid in the identification of individuals with dopaminergic deficit before the onset 
symptoms [80], [121]–[123]. For instance, in PD, 60-70% of the dopamine neurons are 
degenerated and consequently DaT ligand uptake is substantially reduced even at early-stages 
comparatively to aged-matched healthy individuals. This loss in PD is substantially detected in 
DaT SPECT [80], [121]–[123]. Unfortunately, the sensitivity of the DaT SPECT is known to be 
less than 100%, which may be related with SWEDD cases [80].  
Besides, in the comparison of PS, Dat SPECT is limited and does not aid to distinguish  PD, MSA, 
PSP and CBD [80] because DaT SPECT scan only detects loss of DaT which is typical in all PS. 
Consequently, DaT SPECT imaging is not used to differentiate PS. For instance, all of PS have 
abnormal DaT SPECT with asymmetry in the striatum [124] in comparison with healthy subjects 
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but with different progression and pathology. However, even with those changes DaT SPECT is 
only able to differentiate PS and Control groups, as illustrated in the Figure 2.12. [125], [126] 
 
 
 
 
 
Figure 2.12 DaT SPECT images from Control subjects and Parkinson’s Diseases. DaTscan SPECT of a) 
Control subjects, b) PD-patients, c) MSA- patients, d) PSP-patients and e) dementia with DLB. The 
differences between the PS and the healthy group are evidenced in the images but the changes among PD 
and AP may not be comparable because all present evident asymmetries in the striatum. Adapted from [80], 
[123] 
Despite this difficulty of PS distinction, DaT SPECT is very useful to differentiate PS from other 
diseases that have similar symptoms like those manifested in those syndromes [124]. For instance, 
studies reported that the visually analysis of [123I]-FP-CIT SPECT by experts can allow the 
diagnosis of essential tremor and parkinsonism because ET patients present normal a scan which 
indicates that there is no pathological change in the dopaminergic system [127], [128]. 
 In the Figure 2.13, it is enumerated the cases and the groups of subjects that are nowadays 
considered as having normal or abnormal DaT SPECT.  
 
 
 
 
 
 
Figure 2.13 - Normal vs Abnormal DaT SPECT. According to the literature Essential tremor and Dystonic 
tremor present normal DaT scans since there is no degeneration in the basal ganglia. SWEDD PD-patients 
present a normal DaT SPECT but are early diagnosed as having PD. Parkinsonian syndromes are inserted 
into abnormal DaT SPECT since these patients have loss of dopamine.  
2.6 Artificial Intelligence  
Artificial intelligence is a concept that emerged after World War II, and it is used nowadays in 
diverse areas, namely, robotics, bioinformatics, speech and imaging processing, finance and 
chemistry [129].  
Several authors have been trying to define Artificial Intelligence. Haugeland sees AI as the area 
that “makes computers think . . . machines with minds, in the full and literal sense.” [130] and 
Rich and Knight define that concept as “The study of how to make computers do things at which, 
Normal Abnormal 
Healthy subjects PD 
PSP + MAS + CBD 
Genetic Parkinsonism 
Essential/ Dystonic Tremor 
SWEDD PD-patients 
a) b) 
c) d) e) 
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at the moment, people are better”[131]. So far, all the definitions are inserted in two pillars: 
Thinking/Action and Humanly/Rationally, because a computer to be considered intelligent has to 
have human and/or animal characteristics [129]. Those pillars can be divided into four 
approaches: Thinking Humanity, Thinking Rationally, Acting Humanly and Acting Rationally 
[129]. Within of the topic Acting Humanly is Machine Learning (ML). 
 ML as Goodfellow et al. said “is the ability [of computers] to acquire their own knowledge, by 
extracting patterns from raw data”, that is, computers with AI must have the ability to learn from 
data of any situation in the world with an automatic learning process and, thus, predict or make 
decisions based on what have learned [132]. Inside of Machine Learning field is Deep Learning. 
In this subchapter, Deep Learning is explained with especially focus on Convolutional Neural 
Network algorithm and its applications in the medical imaging field.  
2.6.1 Deep Learning  
Deep Learning is a subfield of ML that nowadays have been more used due to the improvement 
of hardware and software [133]. In deep learning, the process of learning is based on getting the 
characteristics of the object. For instance, considering an airplane image, the algorithm extracts 
the colour, the shape of the wings and other characteristics on the image to learn what defines an 
airplane. In AI, these characteristics are called features.  
It is also important to mention that these images are constituted by a bunch of pixels that contain 
a lot of information and that deep learning algorithms are able to extract features at a high level, 
namely, abstract features. For instance, to detect a cat, an airplane, or a face of a human, these 
algorithms first extract small and simple concepts such corners or edges and then extract complex 
concepts, called abstract features, such as objects parts. 
 All these features are extracted by which is called hidden layers [132]. A usually deep learning 
model is constituted by the visible layer, which contains the input image and several hidden layers 
that capture features of the image, first the simple ones then the complex ones as exemplified in 
Figure 2.14. The information travels from one hidden layer to another, that is, the 2nd hidden 
layers extract features from the resultant pixels of the 1st hidden layer and so on. The hidden 
layers are layers that extract indirectly information about the input. 
 
 
 
 
Figure 2.14 Schematic of a deep learning model. Adapted from [132] 
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In AI and consequently, in deep learning, there are two learning process:  
• Supervised learning: in the learning process, also called training, the neural network 
receives the input with the respective label, i.e., the class of the input [132]. Thus, the 
network learns input features by knowing that they belong to a certain class.  
• Unsupervised learning: in this case, the input of the network does not have any 
additional information such as the class that belongs to, that is, the learning process is 
based on the network ability to learn and recognized features from non-label data [132].  
2.6.2 History Behind Convolutional Neural Networks 
In this subchapter, it is briefly described the history of CNN and the progress present in literature 
that originates this algorithm. 
Deep learning can be implemented using Artificial Neural Networks (ANN). ANN architectures 
are based on animal biological neuronal systems [134] and they are considered deep if it have 
more than one hidden layer. All the artificial neural networks are made of computational units 
called neurons, also known as nodes, that mimics neurons in the brain [135] and are connected 
with each other as biological neurons.  
In 1943, McCulloch and Pitts proposed a mathematical approach for an artificial neuron based on 
the biological neurons [136]. This model mimics the synaptic strength by expressing it as the 
weighted sum of n input signals in the neuron minus a threshold. This modulation is represented 
in the Equation 2.1, where positive weights reflect excitatory stimulus and negative weights 
reflect inhibitory stimulus [137]. The 𝜃 is a non-linear function called activation function, 𝑤𝑖 is 
weight of the 𝑖𝑡ℎ input where 𝑖 = 0,1,2,3 … , 𝑛,  𝑥𝑖 is input signal in the neuron and 𝑢 is the 
threshold value, usually 𝑤0 = − 𝑢, and 𝑥0 = 1 [137].  
 
𝑦 =  𝜃 (∑ 𝑤𝑖𝑥𝑖 − 𝑢
𝑛
𝑖=1
) (2.1) 
The Equation 2.1 can also be written as in Equation 2.2 [135]. 
 𝑦(𝑥) = 𝐺(𝑤𝑥𝑇 + 𝑏) (2.2) 
In Equation 2.2,  𝐺 is the activation function, 𝑤𝑥𝑇 is the array of weights and the input array, 
where 𝑇 indicates a matrixial operation called transpose and 𝑏 is the threshold called bias.  
The activation function acts like biological neurons, where when the input overcame a specificity 
threshold, the neuron fire the information across the axon [135]. In this case, the information 
flows to the next neuron and so on in a process called feedforward. A feedforward neural network, 
also known as multilayer perceptron, is a process that occurs from the first layer to the last layer 
without returning to the beginning point or to an intermediary stage [135].  
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The 𝑏 threshold is unique for each neuron and it is responsible to define if the activation of the 
neuron is significant to pass forward in the network. Both weight and bias are trainable 
parameters, that is, the CNN learn and adjusts them in the feedforward process [135]. An example 
of a feedforward ANN architecture and their parameters is represented in the Figure 2.15. 
 
 
 
 
 
 
 
 
Figure 2.15 Feedforward neural network architecture. I is the input layer where xi are the input values, H 
denoted the hidden layers and Z the last layer. W is the weighted array and wij is two-dimensional weighed 
and d1, d2 and dz are neurons. Adapted from [134] 
 
2.6.3 State-of-the-Art of CNN 
Convolutional Neural Networks are one type of ANN usually used for pattern recognition [138], 
[139]. The basis of this network is based on David Hubel and Torsten Wiesel work [132]. These 
two neurophysiologists spend several years studying the visual cortex of cats with specially focus 
on the receptive field cells of the primary visual cortex located in the retina, the area responsible 
for first processing the visual input [132], [140]. 
 The receptive fields cells are sensory neurons that detect light brightness, control the firing of 
visual neurons firing and are divided in simple or complex cells [140], [141]. Simple receptive 
fields cells have two types of subdivisions, the excitatory and the inhibitory and these regions are 
activated only if they receive the specific stimuli, light on or off. Through observation of cells 
mapping, Hubel and Wiesel realized that these cells were sensible to simple features of the input 
such as bars and edges and that and this cells were also able to detect position variations [132], 
[140], [142]. Unlike simple cells, complex cells are insensitive to edges, bars and position 
variations but are able to detect more complex features, such if cells have the same orientation 
[140].   
These findings inspired Fukushima that in 1980 created the first neural network visual cortex-
inspired. This network called Neocognitron was based on the cells of the cat visual cortex [143] 
previously mentioned and it was develop to have the ability to recognized patterns as a human 
Input Values  
Weights  
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been learns using unsupervised learning. The Neocognitron are constituted by two layers: S-Layer 
and C-layer, that are applied one after the other. S-Layers behavior like filters to mimic simple 
cells proprieties of edges and bars detection. In its turn, C-layers receive as input S-layer values, 
and act like complex cells by merging values. This structure was elaborated to be able to recognize 
shapes of the input image based on their geometrical features at any position and without being 
sensitive to small distortions of that shapes. The Neocognitron which means that the network 
learn by itself by receiving as input repetitive stimulus patterns without any additional information 
such as the class that the input belongs to [143]. Fukushima realized that complex cells in the last 
layers started to respond only to a specific stimulus pattern and conclude that Neocognitron was 
able to recognize patterns correctly [143]. 
A few years later, other studies used an Artificial Convolutional Neural Network based on 
Neocognitron to apply to medical imaging for pattern recognition [139], [144]. The structure of 
this Artificial CNN is simpler than the Neocognitron and differ in the fact that it is not constituted 
by C-layers and instead of using unsurprised learning, the automatic machine learning method 
used was back-propagation algorithm, a supervised learning approach [139], [144].  
In 1998, LeCun and colleagues proposed a CNN called LeNet that uses a Gradient-Based 
Learning Approach and the backpropagation algorithm [138]. Even with some similiters with the 
previous CNN algorithms, LeCun proposed an improved CNN structure organized in several 
layers based also in the cat visual cortex. This CNN is constituted by the layers that mimics simple 
cells, the convolutional layers, and by pooling layers that have the same proprieties as complex 
cells. The CNN was training and tested with Modified National Institute of Standards and 
Technology (MNIST) database of handwritten digits [138], [145]. LeCun et al. conclude that 
Gradient-Based Learning improve CNN performance and suggests that CNN is a useful tool to 
feature extraction  [138].  
2.6.4 Convolutional Neural Networks Architecture 
Convolutional Neural Networks are a trainable feedforward neural network constituted by 
multiple stages called layers [138]. CNN are constituted by the input layer, hidden layers and the 
output layer and all of these layers are characterized by having three dimensions: width, height 
and depth [135]. Each hidden layer receives a two-dimension input from the previous layer and 
originates a two-dimensional output. These two-dimensional arrays are called feature maps and 
contain the features extracted [138].  
Concerning CNN architecture, this network is organized in two parts: the feature extraction and 
classification [134]. This network is mainly based on two mathematical operations: cross-
correlation and pooling, that occur in the feature extraction stage.  
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The feature extraction stage is constituted by a convolutional layer, an activation layer and a 
pooling layer.  
The classification part is constituted by a Fully Connected (FC) layer. After FC layer, usually 
there is final layer with a loss function that originates a output traduced by single vector with 
probability scores [135]. 
Therefore, CNN has the following architecture: an input layer receives normalized images with 
the same size [138], convolutional layers, activation function layers, pooling layers, fully 
connected layer and loss function layer. The main layers are illustrated in the Figure 2.16. 
 
 
 
 
 
 
Figure 2.16  Convolutional Neural Network Architecture. This architecture was drawn by LeCun et al. 
[145] to classify handwritten digits of the MNIST database. Between the convolution layer and the 
subsampling layer also called pooling layer is usually an activation layer. After the fully connected layer is 
also a loss function layer. 
The following subtopics are a deep description of each stage and of the components of CNN. 
• Convolutional layer CNN 
Firstly, it is important to notice that CNN has more than one convolutional layer to extract several 
features. Moreover, together with activations functions, it mimics simple cells of the visual cortex 
of the cat [132], [135] by acting like a detector or filter. 
Convolution approach is a mathematical operation that englobes two functions, in which one 
affect the other, to create a third that represents the modifications that that the second function 
caused in the first one [132], [146]. 
 
𝑦(𝑡) = ∫ 𝑓(𝑎)𝑔(𝑡 − 𝑎)𝑑𝑎
+∞
−∞
 (2.3) 
The g function in the Equation 2.3 represent a weight that it is applied to function f. This operation 
is usually represented with and asterisk, Equation 2.4. 
 𝑦(𝑡) = (𝑓 ∗ 𝑔)(𝑡) (2.4) 
In convolutional neural networks the 𝑓 function can be represented as 𝐼 and represents the input, 
an initial image or sets of arrays with visual information. The 𝑔 function is a kernel function 
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usually represented as 𝐾. The kernel is also an array with parameters that are changed by the 
learning algorithm to improve CNN. [132] Both I and K functions are multi-dimensional arrays, 
usually two-dimensional, i.e. matrix, and can be expressed as in Equation 2.5 [132]. 
 
𝑆(𝑖, 𝑗) = (𝐼 ∗ 𝐾)(𝑖, 𝑗) =   ∑ ∑ 𝐼( 𝑖 −  m, j − n)𝐾(m, n)
𝑄−1
𝑛=0
𝑃−1
m=0
 (2.5) 
In the eq.2.5, the convolution is represented by summation over a finite number of the input 
dimensions, 𝑆(𝑖, 𝑗) represents the feature map wherein 𝑖 are the rows and 𝑗 are the columns of the 
image [132]. The input image is a two-dimensional array of size  𝑊 ×  𝐻 where 𝑊 is width and 
𝐻 is height which values are usually pixels. The kernel size is  𝑃 × 𝑄 [135]. Each feature map is 
an image with size 𝑊 − 𝑃 + 1 × 𝐻 − 𝑄 + 1. For instance, an input image of size 8 ×  8  and a 
kernel size of 2 ×  2 originates an output image with 7 ×  7. In CNN, it is common to use the 
Equation 2.5 with some slight differences to guarantee that the kernel function is not inverted 
when applied in the network [135]. Thus, the equation usually applied, also known as cross-
correlation, is expressed in Equation 2.6 [132]. 
 
𝑆(𝑖, 𝑗) = (𝐼 ∗ 𝐾)(𝑖, 𝑗) =  ∑ ∑ 𝐼( 𝑖 +  m, j +  n)𝐾(m, n)
𝑄−1
𝑛=0
𝑃−1
m=0
 (2.6) 
The kernel function is used to extract features from the input image. The kernel is also known as 
filter because its acts like a learning filter where only specific characteristics of the image are 
extracted to proceed to the next layer.[135] Each kernel has weights which are values that indicate 
the importance that the algorithm needs to give to a specific feature. [135] 
The cross-correlation function is applied in the convolutional layer, and basically, the kernel 
convolves across the input image along width and height. The kernel is constituted by local 
receptive fields that are activated when a feature is detected [135] and allow neurons to extract 
all visual features such as corners or edges at any spatial position of the input image or from a 
feature map if the convolution layer is after a pooling layer. 
 After that, CNN learns which weight must give to each feature to allow the activation of the 
receptive fields  [132], that is, the weights of each units in kernel are constantly being adjusted in 
the training process to improve feature detection [135]. Besides, this network it is also able to 
detected these features in any position [138]. 
Then, all these features pass again through other layers to extract high-order features. The 
convolution output contains several features maps in which each map contains information about 
a specific feature. Thus, the convolutional layer output has width, height and depth [132], [135]. 
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• Activation function Layer – Rectified Linear Unit 
The activation layer is usually used immediately after the convolutional layer. This layer contains 
a non-linear function applied element-wise to determine if the values of the convolutional layer 
output traduces important features. Basically, this function defines a threshold that indicates 
which neurons are activated [132], [135]. The advantage of the application of a non-linear 
function it to modulate the linear output as a non-linear function [147]. Thus, CNN can learn and 
modulate any input-output relationship. 
The most common activation function applied to neural networks is Rectified Linear Unit (ReLU) 
[135]. This function is expressed in Equation 2.7 and graphically in Figure 2.17 [132], [135].  
 𝐺𝑟𝑒𝐿𝑈(𝑥) = max {0, x} (2.7) 
When applied to CNN, Equation 2.2 previously mentioned is given as follows, Equation 2.8:  
 𝑦(𝑥) = 𝐺(𝑤𝑥𝑇 + 𝑏) = max {0, 𝑤𝑥𝑇 + 𝑏}  (2.8) 
In Equation 2.8, 𝑤𝑥𝑇 + 𝑏 is the output from linear operations such as cross-correlation and 
pooling and, in this case, the input of the activation layer [135].  
Figure 2.17 illustrates that the activation function sets all the negative values in the feature map 
to zero and all the positive values remain unaltered. In CNN, the negative values that were set to 
zero will not pass forward in the network, that is, that neurons will not fire. Concerning the 
positive values, those will pass through to the following layer because they traduce a meaningful 
feature [132]. 
 
 
 
 
 
Figure 2.17 Graphic representation of Rectified Linear Unit. Negative values x, usually the weights in 
neural networks, are set to zero. Positive values have different values according to their weight. Adapted 
from: [132] 
The main advantage of the activation function such as ReLU is the fact that accelerates the process 
of training and makes it more “effective” as Habibi et al suggest [133]. ReLU has a disadvantage 
called dead neurons, which are neurons that have a negative weight during training and that 
always conducted to zero [135].  
𝐺
𝑟
𝑒
𝐿
𝑈
( 𝑥
)
=
m
ax
{0
,x
} 
0 
0 
x 
2.6 Artificial Intelligence 
 
31 
 
Besides ReLU there are other activation function, such as Sigmoid Function and Hyperbolic 
Tangent Function Tanh, that are represented in Figure 2.18 [135]. However, the literature suggests 
that ReLU is the function that conducts to better results [147], [148]. 
  
 
 
 
 
 
Figure 2.18 Activation Functions. a) Sigmoid Function and b) Hyperbolic Tangent Function. 
• Pooling Layers 
The main objective of adding a pooling layer, also called down sampling, to a neural network is 
to reduce spatial resolution of the output of the previous layer, that is, reduce feature maps size 
[135], [138] only along their with and height. This layer is important to prevent CNN to detect 
features by its position in the receptive field and to reduce their sensibility to ships and distortions 
in the features and consequently reduces overfitting [138]. Besides, once the output is simplified 
and the CNN has to learn less parameters, this layer also reduces computational costs. [133] 
The pooling layer contains a pooling function that changes the output of the previous layer based 
on the information in the nearby outputs [132]. For instance, the pooling operation changes locally 
the feature map which is the output usually from the activation layer.  
In CNN, the most common pooling functions are max pooling, average and weighted average 
[132] and these are functions convolves along the image as a filter. The max pooling operation 
along the input selects a rectangular neighbourhood and within these pixels select the maximum 
value. The output is the maximum values of the rectangular areas considered. In the average 
operation the output value is the average of the rectangular neighbourhood pixels and in the 
weighted average the output is calculated based on distance of the other pixels to the central one 
[132]. According to Sherer et al. the max-pooling presents better results than average pooling 
[135]. In this layer, it is also common to use the stride operation, which it will be explained further, 
to avoid possible overlapping [135].  
• Sparse Connectivity, Shared weights, Zero-padding, Stride in Feature Extraction 
According to LeCun et al, the convolution operation has two important ideas: sparse connectivity 
and shared weights [135] and pooling operation has shared weights. Zero-padding and Stride are 
common both to convolutional and pooling layers. 
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Sparse connectivity: In feature extraction stage, all the layers are organized in the following 
manner: a small portion of one-layer is connected with a single neuron of the next layer. Sparse 
connectivity refers to that connection between layers and it also is related with the fact that the 
kernel size is smaller than the input image which has several pixels [132]. In fact, input image 
size makes almost impossible to connect all the neurons to each pixel, because it would be 
necessary millions of neurons and computational power. Thus, CNN by having sparse 
connectivity, the local receptive fields of the kernel pass through the input image. Then, for each 
small area of the input with the size of the kernel, the output of that area with the kernel is only 
connected with one neuron, as illustrated in Figure 2.19. Even considering that this originates a 
size reduction, it does not affect feature extraction. Besides, even small features can be detected. 
Sparse connectivity does not only increases the statistical efficiency but also reduce the 
parameters needed for learning. [132], [138]  
 
 
 
 
 
 
Figure 2.19 Connection of input layer or one hidden layer with the following layer, in CNN. In feature 
extraction state, each small parts of a layer are connected to only one unit of the following layer. Adapted 
from: [142] 
Shared weights: The shared weights also known as parameter sharing emerged to reduce 
parameters in the CNN and are used in convolutional layers [132], [138]. This means that the 
receptive field used in convolutional layers are always the same for all the image, that is, it does 
not change along the image. Thus, CNN by using the same parameters is able to detect several 
features with just one kernel which values and regardless their position [132]. 
Zero-padding: Zero-padding refers to the addiction of pixels with zero value to the border of the 
resultant feature map. During feature extraction, the size of the features maps decreases due to 
the application of the cross-correlation and pooling operations [132], [135]. Thus, zero-padding 
guarantees that spatial dimensions of the resultant feature map remain the same or with a specific 
dimension [132], [135]. This process is illustrated in Figure 2.20.  
Stride: The stride function is used in situations wherein it is wished to skip some pixels. This 
technique reduces substantially computational costs and possible loss of features information is 
not significant  [132]. An example of stride application in a feature map it is showed in Figure 
2.21. 
Hidden Layer 
Input Layer  
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Figure 2.20  Zero-padding. This figure represents an example of a 2x2 kernel applied to a 6x6 image. The 
output is a 5x5 matrix. The application of the zero-padding equals to 1, in this case, makes the dimensions 
remain the same. 
 
 
 
 
 
 
Figure 2.21 Example of application of a kernel with and without stride. Without stride there is no pixel 
skipping. With stride equals 2, the kernel skips two pixels at once. The s number represents the stride value. 
 
 
 
 
 
 
 
Figure 2.22 Layers at feature extraction vs fully connected layer. At the top, it is represented layers with 
sparse connectivity wherein a and b are the weights, xi are the input and si the output. Each neuron couple 
are connected with only one neuron of the s layer. At the bottom, it is represented a FC layer wherein each 
neuron xi is connected with all neurons of the following layer.  
• Fully Connected Layer  
The fully connected layer is usually connected with the last pooling layer of the network or with 
the last layer of the feature extraction part. Unlike convolutional and pooling layers, in FC layer, 
each unit is connected with each neuron of the previous layer [135] as shown in Figure 2.22. For 
* = 
6 x 6 input image 
2 x 2 Kernel 
5 x 5 output image 
Zero-padding, p = 1 
Without Stride 
(s = 0) 
With Stride 
(s = 2) 
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each input value of FC layer, it is multiplied a weight and it is added a bias [133] which traduces 
on the relation of high-features and classes. In CNN, this layer originates an array with linear 
unnormalized log probability scores as output with n classes, wherein n is the number of classes 
that the input image may belong too [135]. 
• Loss layer 
The loss layer is the last layer of the CNN and consists in the application of a loss function to the 
output obtained in the previous layer, usually a FC layer [132], [135]. This function also known 
as cost function is used to measure the difference between the prediction and the correct value, 
that is the loss [132].  
In deep learning, the most common loss functions are Softmax and Multiclass Support Vector 
Machine (SVM) [149]. 
Softmax function: 
Softmax function also known as multinomial logistic regression basically computes scores from 
the FC layer into a meaningful probabilities scores and calculates the loss based on those scores 
[132], [149]. These values obtained in the FC layer can be represented as a vector k and, basically,  
this vector pass through the softmax layer and originates an output which is a normalized 
probability distribution (between 0 and 1) [132]. Each predictive value in k can be expressed as 
𝑧, wherein 𝑧 = 𝑤𝑥𝑖
𝑇 + 𝑏 .The softmax function is expressed in Equation 2.10 [132], [149] 
wherein 𝑥𝑖 is the input image, 𝑧𝑘 is score obtained and 𝑧𝑗 are the scores along k array in the j
th 
position. ∑ exp (𝑧𝑗)𝑗  is responsible for normalize the scores. Thus, the output of a CNN with a 
softmax function is meaningful normalize probability distribution [132]. 
 
𝑆𝑜𝑓𝑡𝑚𝑎𝑥 (𝑥)𝑖 = 𝑃(𝑌 = 𝑘|𝑋 = 𝑥𝑖)  =  
𝑒𝑧𝑘
∑ 𝑒𝑧𝑗𝑗
 (2.10) 
Regarding the loss value, this is calculated through the log of the probability of the score obtained 
in the FC layer matching to the correct class, as expressed in Equation 2.11 [149] wherein  𝑦𝑖 is 
the real class of the input image and it is an integer and 𝑧𝑦𝑖 is the score that the FC layer gives to 
the correct class. 
 
𝐿𝑖 = −log (𝑃(𝑌 = 𝑦𝑖|𝑋 = 𝑥𝑖))  =  
𝑒𝑧𝑦𝑖
∑ 𝑒𝑧𝑗𝑗
 (2.11) 
Multiclass SVM loss function: 
Multiclass SVM loss function also known as Hinge loss has a different approach to loss 
calculation. Unlike Softmax, this function does not originate an output with meaningful scores. 
Instead, it quantifies how bad was the classifier performance based on loss calculations [149]. 
This function is usually applied when there are multiple classes. 
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This loss function analyses if the score of the correct class is higher than the score of the incorrect 
classes by a margin Δ, a previous stipulated constant. Basically, this function subtracts the scores 
of the incorrect classes with the score of the correct layer. Then, the sum of that difference 
between scores is made and the sum result traduces the loss [149]. The Multiclass SVM loss 
function is expressed in the Equation 2.12, wherein 𝑧𝑦𝑖 corresponds to the score of the correct 
class, 𝑧𝑗 the scores of the incorrect classes and 𝑗 the j
th position in the k array and each 𝑗 correspond 
to one class.  
 𝐿𝑜𝑠𝑠 = 𝐿𝑖 = ∑ max (0,
𝑗 ≠ 𝑦𝑖
 𝑧𝑗 − 𝑧𝑦𝑖 +  𝛥) (2.12) 
This function can be represented graphically as illustrated in Figure 2.23 a). In Figure 2.23 b) is 
illustrated an example of 𝐿𝑜𝑠𝑠 = 0 because 𝑧𝑦𝑖 ≥ 𝑧𝑗  +  𝛥. 
 
  
 
 
 
 
Figure 2.23 Hinge Loss function. a) Hinge Loss b) Hinge Loss wherein the score of correct class (zi) is 
bigger than the incorrect class (zj). 
The total and final loss is given by the sum of the losses in the network, as expressed in Equation 
2.13, wherein N is the number of images in the dataset [132], [149]. This Equation is valid for 
any loss function. 
 
𝐿𝑜𝑠𝑠 =
1
𝑁
∑ 𝐿𝑖(𝑧, 𝑦𝑖)
𝑖
 (2.13) 
• CNN Regularization  
In deep learning, during the learning process the network creates a complex function to modulate 
and describe the outputs. However, sometimes the model fits too well the training data but does 
not fit in the test data and tends to occur underfitting or overfitting [132]. 
Underfitting emerge when the low error values is not good enough, and the network cannot obtain 
good results in the train test and consequently cannot replicate results to new data. Overfitting 
occurs when the CNN model fits to well in the data and the error between the training error and 
the test is to big [132].  
To prevent the network model to overfit is common to add a term in the loss function to allow the 
algorithm to choose the best generalized function that is able to modulate unseen data, the test set. 
a) b) 
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This term penalizes the weights of the neurons by making them small and near zero or by setting 
them to zero which are associated with simple functions [132], [149]. This process is called 
regularization and prevent the network to create overly complex functions. The regularization 
term is given by 𝜆𝑅(𝑊) and thus, the final loss function is given by the Equation 2.14, wherein 
R(W) is the regularization function, 𝜆 a hypermeter called regularization strength and 𝑊 the 
weight vector. The increase of the 𝜆 parameter leads to small weight [132]. 
 
𝐿 (𝑊) =
1
𝑁
∑ 𝐿𝑖(𝑧, 𝑦𝑖) +  𝜆𝑅(𝑊)
𝑁
𝑖=1
  (2.14) 
The most common 𝑅(𝑊) functions used are L1 regularization, L2 regularization and dropout. 
L1 regularization: This regularization, also known as weighted decay, set the weights to smaller 
values, and it is expressed as the squared norm of the sum of all the weights which leads to small 
weights, Equation 2.15 [132], [149]. 
 𝐿1:     𝑅 (𝑊) = ∑ ∑ 𝑊𝑘,𝑙
2
𝑙𝑘
  (2.15) 
L2 regularization:  This regularization, set some weights to zero, and it is expressed as the norm 
of the sum of all the weights, Equation 2.16 [132], [149]. 
 𝐿2:     𝑅 (𝑊) = ∑ ∑ |𝑊𝑘,𝑙|
𝑙𝑘
  (2.16) 
Dropout:  This regularization is usually placed after FC. Dropout consists in temporally remove 
random neurons during training process in forward pass to increase the ability of the network to 
learn the weights more precisely [132], [150]. An example is illustrated in Figure 2.24. Thus, the 
network act like if it was training several networks because it is training several subnetworks with 
different neurons removed. Even though it increases the time of training this does not lead to 
computational costs [150].  
 
 
 
 
 
 
Figure 2.24 Dropout layer. a) CNN structure without dropout b) CNN structure with a dropout layer. 
Adapted from: [150] 
 
a) b) 
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• CNN Training 
In AI, the intent of training is to find the weights and biases that minimizes the loss function, that 
is, which values minimizes the discrepancy between the real class and the output [132]. One of 
the most successful approaches to train a neural network is the Gradient-Based Learning [145] 
because those parameters are updated very faster. In this case, the loss function minimization is 
achieved by the calculation of its gradient with respect of weights [138].  
In CNN, it is usually used the Stochastic Gradient Descent (SGD) to adjust the weights. SGD is 
obtained using the backpropagation algorithm. Basically, this algorithm computes the negative 
gradients that faster minimize the loss function and send them backwards to beginning of the 
network to adjust the weights. Then, these update weights are propagated forward in the network 
and the process repeats until the error/loss is minimized.  
The SGD is a linear combination of the previous weight update, 𝑉𝑡, and the negative gradient 
∇𝐿(𝑊𝑡). The weight update is expressed in Equation 2.17 and Equation 2.18, wherein 𝑡 is the 
iteration number, 𝜇 momentum, 𝛼 is the learning rate, 𝑉𝑡+1the update value, 𝑊𝑡+1the update 
weight and 𝑊𝑡 the previous rate [151]. 
 𝑉𝑡+1 = 𝜇𝑉𝑡 +  𝛼∇𝐿(𝑊𝑡) (2.17) 
 𝑊𝑡+1 = 𝑊𝑡 +  𝑉𝑡+1 (2.18) 
The parameters  µ and 𝛼 are hyperparameters, where the momentum, µ, is the weight that indicates 
how much the previous weight influence the weight of the following layer, and the learning rate, 
𝛼, is the weight of the negative gradient [151] 
It is important to notice that the initialization of the weight, bias and hyperparameters is made 
according to specific methods that will not be explored in this work. 
2.6.5 State-of-the-art: CNN applications to Medical field 
CNN have many applications in several fields, such as, traffic signs identification [135], video, 
speaking and image recognition [152]. The usage of this AI algorithm has been increasing through 
the years due to the improvement of the computer power and because it has been proved that CNN 
are useful in those areas [132], [135], especially in the medical field [24], [25], [153], [154]. 
For instance, in 1995, a study used CNN for microcalcifications detection in digital mammograms 
and lung nodules on radiographs [139]. Later, in 1996, Sahiner et al. performed abnormal mass 
and normal breast tissue classification with recourse to CNN [144]. 
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In 2017, Zou et al. used a 3D-CNN to classify Attention Deficit Hyperactivity Disorder with 
structural and functional MRI and conclude that a multi-modality approach is useful to find 
neuroimaging biomarkers in brain related diseases [155].  
Regarding neurodegenerative diseases, Pereira et al. used CNN to classify electric signals of PD 
patients and healthy subjects [156]. These electric signals translate the tremors of the hand when 
subjects are drawing specific figures such as circles and spirals. Then, the electronic signal was 
converted into a time series-based image and tested with several CNN types [156].  
Liu et al. proposed a 3D cascaded CNN to study Alzheimer’s Disease (AD) in multi-modality 
approaches [24]. The study was conducted with MRI and PET images of 93 AD-patients, 204 
mild cognitive impairment (MCI)patients and 100 control subjects. The MRI and PET images 
where divided into 3D local patches. Then to each patch is was assigned a 3D CNN to extract the 
high-level features. After that, all the high-level features were compacted, and then they were the 
input of a 2D CNN. The 3D CNN was constituted by convolutional and pooling layers with three 
dimensional kernels and 2D CNN was formed by two consecutive convolutional layers, two fully 
connected layers and one softmax layer. The 3D CNN and 2D CNN architectures are illustrated 
in Figure 2.25.   
 
Figure 2.25 Multi-modality cascaded CNN architecture. This CNN was drawn by Lio et al. [24] 
The authors conclude for the approach proposed there is no need for segmentation and rigid 
registration steps in the image pre-processing steps and that comparatively with other 
classifications models, this new method present higher accuracy. The results obtained in this study 
was 93.26% accuracy for AD vs Control classification and 82.95% accuracy for MCI vs controls 
[24]. 
CNN were also applied to Multiple Sclerosis identification. A study conducted by Zhang et al., 
obtained 98.23% accuracy, 98.22% sensitivity and 98.24% specificity [154]. In this study 
participated 38 patients and 26 healthy controls. Each image was divided into slices and those 
which contained the regions associated to Multiple Sclerosis pathology were collected to the 
classification. To increase the data training, the authors performed data augmentation by applying 
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the following methods: rotation, gamma correction, noise injection, random translation and 
scaling. The CNN was constituted by 7 convolutional layers, 3 fully connected layers, dropout 
layers and the parametric ReLU layer. The authors conclude that the introduction of dropout and 
the parametric ReLU increases CNN accuracy [154].  
CNN have also been used for medical imaging segmentation. For instance, Karimi et al. study 
showed that a CNN-based segmentation framework was able to predict the coordinates of the 
prostate surface based on prostate MRI images [157] and Chen et al. used CNN to brain tumour 
MRI image segmentation [158].  
Moreover, CNN was also applied to the classification of DaTScan SPECT and MRI images. The 
following subchapter describes studies that used CNN to classify PS as well as other machine 
learning techniques used for the same propose. 
2.7 State-of-the-art: Classification methods for PS   
Through the years, several approaches have been used to attempt to classify PS. In 2017, Choi et 
al. designed a 3D-CNN to classify DaTScan images of early PD-patients, SWEDD patients, 
control (healthy) subjects and patients with non-PS [25]. Besides classification with CNN, the 
authors also analysed the performance of professionals. The images were extracted from the PPMI 
database and from the Seoul University Hospital. The 3D CNN, PD Net, is illustrated in the Figure 
2.26. This 3D-CNN is constituted by 3D-convolutional layers interleaved with pooling layers 
with the max pooling function, followed by a ReLU function, a FC layer and the softmax layer. 
The input images were normalized by the range 0 to 255 and zero-padding was also applied. The 
training process was performed with stochastic gradient descent. The training and validation sets 
were executed using images from PD and control subjects. The classification of SWEDD subjects 
were performed using the pre-trained PD Net with PD and Control images to obtain a result of 
“normal” or “abnormal” image. Then, the prediction was compared with the diagnosis of the 
PPMI database. Concerning PD patients, in the test set it was obtained 96.0% accuracy, 100% 
specificity and the 94.2% Sensitivity. The authors also verified that these results are higher than 
those achieved by the visual and conventional quantification [25].  
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Figure 2.26 Deep convolutional neural network for DaTscan SPECT images classification designed by 
Choi et al. [25].  
Another study conducted by Martinez-Murcia also used CNN to distinguish DaTscan SPECT 
images of PD-patients, SWEDD patients and Healthy subjects. Firstly, using a traditional CNN, 
similar to the one designed by LeCun et al., it was classified PD vs Control which result in 95.5% 
accuracy, 96.1% sensitivity and 94.5% specificity. Then, it was classified PD vs Control vs 
SWEDD which leads to 82.0% accuracy [153].   
Moreover, Esmaeilzadeh et al. developed a deep learning framework for PD classification with 
3D-CNN using MRI images. The architecture of the network is constituted by 3 blocks of 2 
convolutional layer and 1 pooling layer wherein the activation function for each layer is the 
Leaky-ReLU, two fully connected layers and one softmax layer. Besides MRI images, the authors 
also tested an approach of introducing two features in the last FC layer: age and sex. The 
introduction of these two variables increases the accuracy of the classifier. Furthermore, to a better 
understanding and visualization the output of the CNN model they create a Parkinson Heat-Map 
of Brain of the axial, sagittal and coronal views. These maps are images with a colour scale that 
translates the most significant and critical areas in the image that the CNN considered as an 
important feature as illustrated in Figure 2.27 [22].. In this case, it coincides with the pathological 
regions in PD: Substantia Nigra, Basal Ganglia and the Superior Parietal [22].  
 
 
 
 
Figure 2.27 Parkinson Heat-Map of Brain in the Esmaeilzadeh et al study. a) Coronal view b) Axial view 
c) Sagittal view. At blue colors indicate the critical regions for PD diagnosis. Adapted from: [24] 
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Besides CNN, other approaches have been used to analyze and/or classify SPECT images. Some 
studies used a fully automated Objective Striatal Analysis (OSA) to calculate the striatal binding 
ratio [159]–[161]. The striatal binding ratio is a measure used by specialists to analyse the SPECT 
images, since this ratio is different in PD-patients in comparison with healthy subjects. This ratio 
is given by the ratio of striatal region and the occipital minus 1 [162].  
Regarding OSA, in a succinctly explanation, in this technique the DaT SPECT images are re-
oriented with a standard average template and the algorithm OSA automatically detects the 
striatum and the occipital structures and calculate the binding ratio of these structures [159]. Once 
this ratio is lower in PS patients [116], this algorithm is able to detect that difference in comparison 
with healthy subjects and that is why it is considered an useful tool [160]. A study that made usage 
of this technique achieved similar ratios to those manually obtained by a specialist [159]. 
Interestingly, OSA allows the detection of the laterally asymmetry in the dopamine of the striatum 
[161] which causes unilateral symptoms [163].  
Besides OSA, Machine Learning methods such as SVM were also used for PS diagnosis [164]–
[166]. SVM is a supervised learning algorithm used for pattern recognition [167].  
Briefly, SVM is an algorithm that transforms the input vectors into a feature map space that is 
filled with points originated from the training process. Then this feature map has a hyperplane, 
the optimal mathematical model, that works like a decision boundary to separate training data 
points from each class. The best hyperplane is the one that optimizes the algorithm, that is, the 
hyperplane that it is maximally distant from both classes and that best divide them [167]. In 
complex cases, wherein, the training data points from the both classes are mixed and the linear 
hyperplane is not able to divide the points of each class, it is usually used kernel techniques [168]. 
Prashanth et al. used SVM to classify SPECT images of early PD-patients and controls and 
performed a logistic regression to estimate the risk of PD. The SVM classification was performed 
using the striatal binding ratio as a feature, and it was obtained an 96% accuracy using a kernel 
and 92% accuracy when used linear SVM [164]. Other studies using SVM and SPECT images  
classified early-PD and controls based on the side of the brain that was affected [166].  
In 2015, Oliveira et al. obtained a high accuracy result with the SVM using a voxels-as-features 
approach [21]. The classifier achieved 97.86% accuracy using specific voxels of the volume of 
interest as features for the SVM. These voxels were from the cortex and occipital area [21]. Other 
study elaborated by Tagare et al. that also used a voxel-based logistic analysis reveal that voxels 
in the caudate, the putamen and globus pallidus are useful for PD and Control classification. 
Moreover, this approach could distinguish SWEDD-patients from PD-patients, but not SWEDD-
patients from control group. They also develop a new method called logistic component that 
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revealed interesting findings related with age and sex of the subjects. In fact, this study showed 
that exists a normal increase of dopaminergic degeneration due to aging but that it is smaller and 
less significant in comparison with PD-Patients. Moreover,  the authors also showed that there is 
no evidence of difference in the dopamine degeneration between female and male PD-patients 
[20]. 
Regarding MRI images studies that also used other algorithms than CNN, Singh et al. also used 
two combined machine learning algorithms to classify T1-weighted images of PD, SWEDD and 
control subjects of the PPMI database. Those methods were an unsupervised Self-Organized Map 
(SOM) used for feature extraction and a supervised learning based Least Squares Support Vector 
Machine to classification (LSSVM). The (SOM) algorithm was able to detect the biomarkers that 
differ SWEDD from PD and the test was performed by dividing the data set in two groups: Age-
unrelated groups and age-related groups. The case that they considered that had the best 
performance was when it was used age-related groups and LSSVM classifier obtained  99% 
accuracy for PD vs SWEDD [169].  
Other study performed by Duchesne using also T1-weighted MRI images to classify PD, PSP and 
MSA achieved higher accuracy results (90.6%) and 93.3% sensitivity and 88.2% specificity. They 
used features from the characteristics of the hindbrain in the MRI images, namely shape and 
intensity,  as input for the SVM algorithm [170]. Salvatore et al. also applied SVM algorithm to 
distinguish PD from PSP. The authors performed a voxel-based analysis and conclude that best 
areas to discriminate this two PS were: midbrain, corpus callosum and thalamus [171]. Zhang et 
al. discriminate PD and ET using machine learning framework based on SVM and statistical 
analyses for classification. The significant features were extracted with the Principal Component 
Analysis technique from the most significant regions of interest: caudate, calcarine and right 
medial frontal gyrus. The resulting accuracy was 84.54%, 84.48% and 87.22% for caudate, 
calcarine and right medial frontal gyrus, respectively [172].  
 
 
 
 
 
 
 
 
  
 
 
 
Chapter 3 Methodology  
 
This section is divided in four main topics: study population, MRI and DaTscanTM pre-processing 
steps, train, validation and test set formation and CNN architecture. Firstly, it is presented the data 
population selection, the criteria for data extraction and data set formation will be explained. 
Secondly, the pre-processing of the MRI and SPECT images will be described as well as the 
formation of the slices that will be used for the classification. Then, the CNN framework used in 
this work will be described together with the parameters and images used for train, validation and 
test sets. Lastly, the methods used for the evaluation of the model performance will be presented 
and described as well. 
3.1 Study population 
The images used in this study were extracted from the PPMI database. PPMI is an international, 
multi-center and longitudinal study constituted by data that came from several clinical sites in the 
world, such as, United States, Europe, Israel and Australia [173]. 
This database is a landmark for the clinical study of PD progression and its goal is to improve the 
understanding of the disease and boost the research to refine the PD therapeutics and adequate it 
for each patient [174]. PPMI is comprised of biological samples, clinical behavioural assessments 
and medical images obtained from different techniques based on standardized protocols. These 
biomarkers are available for the scientific community to aid the investigation, study and 
identification of biomarkers related with PD progression [174].    
In the present moment of this study, the database was constituted by a total of 26295 brain scans 
and 1184 participants. These participants are divided into six cohorts according to their 
characteristics, diagnoses and exams results. The six cohorts are: 
• Control Subjects: This group is comprised by health participants who are 30 years or 
older and do not present first degree blood relatives with PD. This exclude the risk of the 
disease being inherited from relatives [175]. 
• de novo PD subjects: This group contains participants early-diagnosed with PD (up two 
years) and that never were medicated with PD medication [175]. 
• Prodromal subjects: These participants do not have PD but were diagnosed with 
hyposmia or sleep behaviour disorder, which are features that may suggest the beginning 
of PD [175].  
• SWEDD subjects: This group contains people early diagnosed with PD that present a 
normal DaTscanTM  [175]. 
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• Genetic Cohort Subjects: This group is comprised by subjects who have a genetic 
mutation in a specific gene, and that were diagnose with or without PD [175]. 
• Genetic Registry Subjects: This group is comprised by subjects diagnosed with or 
without PD who have a genetic mutation or a first-degree relative [175]. 
 
All subjects, except controls, had been submitted to the cognitive tests MoCA, and two motor 
assessments MDS-UPDRS and Hoehn and Yahr scale performed in PPMI clinical sites.  
 
PPMI is constituted by several brain scans obtained from different medical imaging techniques: 
Computed Tomography (CT), Diffusion Tensor Imaging (DTI), SPECT, Positron Emission 
Tomography (PET), MRI and Functional Magnetic Resonance (fMRI) [174]. Although, all of 
these techniques are important for PD study [84], in this work it only will be used images acquired 
with MRI and SPECT. Moreover, it was also needed that the subjects in the study had some 
characteristics in common. Therefore, exclusion criteria based on 7 criteria were applied as 
described in the following section and summarized in Table 3.1. 
3.1.1 Exclusion and inclusion criteria  
1. Group Exclusion:  
This study is focused on PD, SWEDD and Healthy subjects due to the need to 
distinguish them. Therefore, all groups except de novo PD, SWEDD and Control were 
excluded. After this selection, the data sample was comprised by 23163 images and 
749 participants. 
2. Images Exclusion:  
As referred previously, only MRI and DaTscanTM SPECT images were used. On one 
hand, MRI images give anatomic information and allow to find changes in 
pathological brains when compared to controls. On the other hand, DaTscanTM 
provides information about striatum function. After this selection, the data sample was 
comprised by 7831 images and 749 participants.  
3. Exclude pre-processing MRI data:  
In PPMI, some MRI are already processed. Since in this study it is needed that they 
must undergo the same processing, only the original MRI images will be considered. 
SPECT images do not need this criterion because PPMI only have pre-processed 
DaTscan images. After this selection, the data sample was comprised by 6425 images 
and 749 participants. 
4. T2 and PD MRI images exclusion:  
- The PPMI database consists of several MRI images, namely Proton Density Weighed 
(PD-W), T1-W image an T2-W images. In this study only the T1-W images will be 
used due to the following reasons: 
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- The conventional T1-W images have been considered important for the study of PS 
because they can translate biomarkers that indicates structural changes that occur 
during the progression of these diseases [84].  
- In fact, T1-Weighted images are usually used for distinguishing PS such as PSP from 
PD and normal subjects [176]. This happens because PD patients present subtle 
changes in T1-Weighted images unlike other PS that have visible changes in MRI 
images [84]. 
- Besides, T1-Weighted can also detect changes in putamen volume in both early and 
advanced stage of PD [95].  
After this selection, the data sample was comprised by 3130 images and 749 
participants.  
5. MRI exclusion according to their acquisition characteristics: 
 PPMI database is comprised by several T1-weighted MRI images which have 
different acquisition parameters from each other such as the magnetic field, sequence 
acquisition and their dimension (2D or 3D). According to the literature, 3D images 
have higher spatial resolution than 2D images [177]. This is due to the fact that 3D 
images have a smaller section thickness that ensures that there is no loss of spatial 
information, which does not happen with 2D images [178]. Regarding the intensity of 
the magnetic field, it is possible to obtain good results with either 1.5T or 3T [179]. 
Images acquired with 3T allow that early stages of PD can be detected, but whether 
3T or 1.5T, good results can be obtained to detect  PS using both intensity scans [95], 
[180]. Moreover, according to the Canadian Agency for Drugs and Technologies in 
Health, it cannot yet be clinically concluded that 3T is more effective than 1.5T since 
it cannot be ascertained whether or not patients receive a personalized treatment and 
whether or not it translates into a different clinical outcome [181]. Thus, according to 
this, all the 3D T1-W images which acquired whether with 1.5T or 3T were included 
in this study. After this selection, the data sample was comprised by 3111 images and 
749 participants.  
6. Subjects must have both exams - MRI-SPECT pair:  
This criterion is one of the most important. To compare images from different imaging 
techniques and to guarantee that SPECT images are adjusted to the respective subject, 
it is mandatory that each subject has at least one T1-weighted image and one 
DaTscanTM SPECT. Thus, all the participants that only have one MRI image or one 
DaTscanTM were excluded. After this selection, the data sample was comprised by 
3085 images and 728 participants.  
7. Selection of MRI and SPECT images with the closest dates: This criterion joins 
SPECT and MRI images that have the closest acquisition dates with the aim to form 
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image pairs. According to National Institute for Health and Care Excellence of the 
United Kingdom, patients with PD should be seen regularly to review their diagnosis, 
with intervals of 6-12 months [182]. In PPMI, there are participants that have more 
than one DaTscanTM or more than one T1-W image. In these cases, it is necessary to 
select which exam will be used to form MRI-SPECT pair. Thus, the MRI and SPECT 
exams that are selected to form a pair are the ones with closest dates, that is, the ones 
that only differ in a maximum of 6-12 months. Besides, since PPMI is a longitudinal 
study, several subjects have more than one SPECT and MRI pair. In this work it was 
considered one MRI-SPECT pair for each subject at baseline. After this selection, the 
data sample was comprised by 1244 images and 622 participants. 
Table 3.1 Exclusion Criteria for Population of the study 
Data Criteria 
PPMI 
Images = 26295 
Participants = 1184 
 
 1st Exclusion criterion: 
Exclude all the groups except: Control, SWEDD 
and de novo PD 
After application of 1st Exclusion criterion: 
Images = 23163 
Participants = 749 
 
 2nd Exclusion criterion.: 
Removal of all the exams that will not be used  
(DTI, CT, fMRI and PET)  
After application of 2nd Exclusion criterion: 
Images = 7831 
Participants = 749 
 
 3th Exclusion criterion: 
Exclude all the processed MRI data 
 After application of 3nd Exclusion criterion: 
Images = 6425 
Participants = 749 
 
 4th Exclusion criterion: 
 T2-W and PD-W MRI images exclusion 
After application of 4th Exclusion criterion: 
Images = 3130 
Participants = 749 
 
 
 
 
 
 5th Exclusion criterion: 
MRI exclusion according to their acquisition 
characteristics 
After application of 5th Exclusion criterion: 
Images = 3111 
Participants = 749 
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 6th Exclusion criterion: 
Subjects must have both exams  
After application of 6th Exclusion criterion: 
Images = 3085 
Participants = 728 
 
 7th Exclusion criterion: 
Selection of MRI and SPECT images with the 
closest dates and at Baseline where each subject 
only have one MRI and SPECT pair 
After application of 7th Exclusion criterion: 
Images = 1244 
Participants = 622 
 
 
3.1.2 MRI and SPECT Acquisition  
MRI and SPECT images used in this work were acquired in clinical sites of PPMI. This 
acquisition is based on a standard protocol developed by PPMI [174]. Although acquired with the 
same protocol, it is also important to notice that the images were acquired in MRI machines from 
different companies. As previously referred, those images were acquired at Baseline [183]. The 
3D T1-Weighted images used in this study were acquired from Sagittal or Axial planes [183]. 
Regarding DaTscanTM SPECT images, those are acquired after 4±0.5 hours after the radiotracer 
Ioflupane I123 injection  [184].  
The acquisition parameters of the MRI and SPECT images used in this work are described in the 
Appendix A. This information was extracted of the header of the DICOM MRI and DaTscan brain 
scans and from the PPMI database website (https://ida.loni.usc.edu/login.jsp). 
3.1.3 Statistical data sample analysis 
In this dissertation, it is intended groups with age and sex matched. Thus, the PD patients, 
SWEDD patients and Control subjects were considered categorical independent groups, wherein 
the age of each subject is a numerical variable and sex is a categorical variable. Then, it is was 
performed the Mann-Whitney U Test to test if there are age differences between the groups and 
the Chi-Square Test to test if there are associations between the sex of the groups since for the 
subjects of those groups must share similar characteristics to allow a reliable comparison.  
Mann-Whitney U Test is a non-parametric test used to compare differences between two 
independent groups, when the dependent variable is numerical or ordinal [185]. In its turn, Chi-
Square Test is used to detect if there are any relationship between two categorical variables [185]. 
Both methods test the Null hypothesis (H0). This hypothesis postulates that there is no difference 
two phenomena using Mann-Whitney U Test and no relationship using Chi-Square Test [186]. 
The Null hypothesis is rejected when a value, called p-value, is less than a significant level. In 
this work, it was considered that the significant level is 0.05 because it usually the suggested by 
3.2 MRI and SPECT pre-processing and registration 
 
48 
 
the literature. Thus, if the p-value is less than 0.05, there is a significant difference for Mann 
Whitney U test  or association between two groups using Chi-Squared Test. Otherwise, if the p-
value is higher than 0.05, then there is no significant difference or association [185] depending 
on the test used. Both Mann Whitney U and Chi-squared tests were performed using the SPSS 
software.  
3.2 MRI and SPECT pre-processing and registration 
The principal aim of this procedure is to align brain scans even coming from different subjects 
into a common space using a standard template. All the pre-processing steps performed in this 
study followed typical procedures described and used in the literature [24], [25], [123], [187]. 
Firstly, both type of images, MRI and SPECT, were downloaded in Digital Imaging and 
Communications in Medicine (DICOM) format. After extracted, T1-Weighted and DaTscan 
images were converted from DICOM to Neuroimaging Informatics Technology Initiative (NIfTI) 
format with Statistical Parametric Mapping 12 (SPM) and dcm2nii – Neuroimaging tools & 
Resources Collaboratory, respectively. This format is the most used format in imaging pre-
processing programmes because it facilitates data analysis [188]. 
Concerning the MRI pre-processing steps, they were performed using SPM12. SPM12 is an 
academic toolkit develop by Wellcome Trust Centre for Neuroimaging at University College 
London for functional data analysis and image processing based on statistical and mathematical 
concepts [189]. The pre-processing steps were: Anterior Commissure (AC) – Posterior 
Commissure (PC) alignment correction, bias regularisation, affine registration to Montreal 
Neurological Institute - International Consortium for Brain Mapping (MNI-ICBM) brain 
template, spatial normalisation, and smoothing. These steps were performed as follows: 
1. The AC – PC alignment correction was manually performed to ensure that the T1-Weighted 
images have the closest orientation to the template and to facilitate the following steps [190]. 
This was executed using the “Display” option of the SPM12 interface; 
2. To to reduce artefacts in MRI images and correct non-uniform intensity inhomogeneities 
caused by high-fields, it was applied bias regularisation = light regularisation (0.001) and Bias 
Full Width at Half Maximum (FWHM) = 60 mm cutoff (default values). This step was 
performed using the “Segment” option. 
3. Affine registration was performed to register the MR images to the MNI- ICBM template. 
This process was performed with the “Segment” option. This step allows the formation of 
Deformation Fields images which are images that express information about the shapes of the 
subject brain and traduces the amount of displacement of these shapes in the location of 3D 
space [191]. Then, the Deformation Fields are used in the following step to complete the 
registration process.  
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4. Spatial normalization was used to handle scans into standard stereotactic space [191]. This 
step was performed using “Normalize: Write” with the deformation fields obtained in the 
previous step. 
5. Smoothing is used to improve signal-to-noise ratio, reduce artefacts in MRI images and correct 
non-uniform tissue intensities 2. This step was performed using “Smooth” option with FWHM 
=2 [191], [192].  
Regarding SPECT images, the DaTscanTM were already pre-processed when extracted from 
PPMI. According with the information provided by PPMI [193], SPECT raw projection data were 
acquired at PPMI Imaging centres and were sent to the HERMES (Hermes Medical Solutions, 
Stockholm, Sweden) to be reconstructed with the system for iterative reconstruction based on 
hybrid ordered-subset expectation maximisation, an algorithm for image reconstruction. In this 
step, no filters were applied [193].  Then the subsequent processing was applying a standard 3D 
Gaussian 6.0 mm filter to the resultant image. [18] Following that, all the scans were normalized 
to Montreal Neurologic Institute (MNI) space, a template that was created based on healthy young 
subjects [193].  
Therefore, in this study, the only processing step that was performed to the SPECT images were 
the co-registration with the MRI images resultant from the smoothing step. The co-registration 
allows that SPECT and MRI images have the same spatial normalization. All DaTscanTM were 
co-registered with the respective T1-weighted image of the same subject. This was performed 
using “Coregister: Estimate & Reslice” option [192].  
3.2.1 Input images 
In clinical practice, the conventional medical images are 2D images [27], since 3D images present 
higher time of acquisition [194]. Thus, the 3D pre-processed MRI and SPECT images were 
divided into two-dimensional slices in PNG format which is compatible with software application 
used [195]. The slices were obtained from the Axial anatomical view illustrated in Figure 3.1.  
 
 
 
 
Figure 3.1 Anatomical planes of the brain. The Coronal view separate the front from the back of the brain. 
The Sagittal separates the left side from the right side. The Axial view is from the bottom of the brain to 
the top and it is the one used in this study. Adapted from [196]. 
Both MRI and SPECT images have the same dimensions due to the registration process, 
79x95x79 voxels. Thus, each 3D Axial and each DaTscanTM image was divided in 79 slices. One 
Sagittal Coronal 
Axial 
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example of the slices obtained of one healthy subject is represented in the Appendix B. Each 
Axial slice has a size of 79x95 mm2. The division in slices was performed using MATLAB. 
After the division, it was applied a Contrast Limited Adaptive Histogram Equalization (CLAHE) 
to the resultant slice that were used in the classification. The CLAHE is an approach based on the 
Histogram Equalization (HE).  HE is an image processing method used to increase the quality of 
the images based on contrast enhancement [197]. Basically, the HE uniforms the greys levels of 
an image using a histogram that reflects the uniform distribution of that grey levels. In its turn, 
unlike HE, CLAHE has a local approach in which it is performed an histogram for each region of 
the image [197]. The CLAHE was performed with the function “adapthisteq” of the MATLAB.  
3.3 Classification with Convolutional Neural Networks 
3.3.1 MedCNN and Caffe 
In this study, it was used an application based on the deep learning framework Caffe. This 
application called MedCNN: convolutional neural networks for medical applications was 
developed by Godinho at Institute of Biophysics and Biomedical Engineering (IBEB) to be 
applied to the classification of biomedical signals and medical images  [195].  
Caffe is an open source framework of deep learning algorithms namely convolutional neural 
networks, developed by Berkeley AI Research. Caffe makes use of Graphics Processing Units, 
known as GPU, to fasten computation than using only the CPU [198]. GPU are powerful 
electronic circuits that are able to increase the parallel computing with a good energy efficiency 
[199], Figure 3.2.  
The Caffe framework is comprised by C++ libraries, Compute Unified Device (CUDA®) and 
Blobs. All the implementation of this framework is C++ based [198] and the acceleration of Caffe 
computation [135] is performed by CUDA and cuDNN library , develop by NVIDIA [200]. The 
Blobs act like Protocol Buffers. Protocol Buffers are methods that serialize data, that is, convert 
data to formats for storing and communication [201] and they are compatible with several 
programming languages.  
In its turn, Blobs are 4-dimensional arrays to store and communicate data within Caffe libraries 
[198]. Usually, Blobs stores batches of images and parameters of the network [198]. In this case 
that large-data is used, the data is store in Lightning Memory-Mapped Database Manager 
(LMDB) format. The LMDB library stores the data as byte arrays and it is characterized by its 
memory efficiency and elevated performance [202].  
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Figure 3.2 GPU versus CPU. During GPUusage, several of operations are performed by the GPU while 
CPU just runs some code.  GPU has thousands of cores to process work in parallel and intensive functions, 
like shown in the image, e.g., three lines are processed at the same time unlike CPU which only have 
multiple cores and process in a serial sequence and one line at once. Adapted from: [200]  
 
Caffe also provides interfaces for MATLAB and Python [198]. For instance, the MedCNN 
interface was developed using Python code [195]. See Figure 3.3 
 
 
 
 
 
Figure 3.3 Framework Caffe and MedCNN application. Protocols Buffers, C++ and CUDA allow the 
criation of the Caffe Library that contains files that can be used by the Caffe user. The MedCNN application 
was develeoped using the python interface. Adapted from:[135] 
Concerning the installation process of both Caffe and application of MedCNN, firstly is installed 
CUDA 8.0 and respectively cuDNN, followed by some Caffe dependencies required and 
described at Caffe website. The Anaconda Python 2.7 is also installed to allow the use of Caffe 
python code. Then, the framework Caffe is installed and MedCNN can be lunched trough the 
Spider, a python development environment, of Anaconda.  
In this work, it was used a CentOS Linux 7, with the processor Intel® Xeon(R) CPU E5530 @ 
2.40GHz × 4 and the graphic card GeForce GTX TITAN X/PCIe/SSE2. This GPU is 
characterized by its high performance due to its features: 3072 CUDA cores, 7.0 Gbps of memory 
clock and 12 GB of random access [200] which make it one of best NIVIDIA graphic cards [203]. 
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3.3.2 CNN architecture  
The MedCNN application works with the following network architecture. Firstly, the input data 
of the untrained network (the PNG slices) are converted to the LMDB format and scaled to 1/255 
to set the intensity of the pixels of the image into a range of 0 to 1 to guarantee an intensity 
normalization of the images [204]. This scaling also enables faster computing since set all the 
inputs with the same covariance which helps in calculations in the training process [205]. Then, 
the data pass through the CNN architecture designed in the Figure 3.4.  
Figure 3.4 CNN designed in the MedCNN application and adapted to this study. The input and features 
maps have size denoted as Height x Width (Caffe notation). Adapted from: [195] 
This CNN is inspired in the LeNet develop by LeCun et al. [138] and used in Godinho work [195]. 
As illustrated in Figure 3.4. The CNN is comprised by the following order and layers: 
• Convolutional layer with a kernel size of 5x5, stride equal 1 and an output of 100 
features maps in the first layer and 200 features maps in the second layer; 
• Pooling layer with max-pooling function, kernel size of 2x2 and stride equal 2 and 
an output of 100 features maps; 
• Convolutional layer with a kernel size of 5x5, stride equal 1 and an output of 200 
features maps; 
• Pooling layer with max-pooling function, kernel size of 2x2 and stride equal 2 and 
an output of 200 features maps; 
• Inner Product Layer, the Fully Connected layer originates 100 output values 
• Activation layer with the ReLU function  
• Inner Product Layer: from the Fully Connected layer results 2 outputs which are 
the number of classes that the image may belong to. 
• Softmax layer with the Softmax loss function.  
A weight filler was applied to all layers except ReLU and Softmax layers. A weight filler is an 
algorithm that initializes the weights. In  this work, it was applied the weight filler Xavier which 
is based on Glorot and Bengio study [206], and basically set the initial values of the weights based 
on the number of inputs and output nodes. 
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For the learning process it was used the SGD with the Backpropagation algorithm. In this 
procedure, it was performed a learning rate decay policy that defines how the algorithm learns the 
weights.  
In this approach, it was used a learning rate decay policy defined as 𝛼𝑖𝑛 × (1 +
𝑔𝑎𝑚𝑚𝑎 ×  𝑖𝑡𝑒𝑟)− 𝑝𝑜𝑤𝑒𝑟, wherein 𝛼𝑖𝑛 is the initial learning rate, 𝑔𝑎𝑚𝑚𝑎 is a value that drops 
the learning rate, 𝑖𝑡𝑒𝑟 is the current iteration, and 𝑝𝑜𝑤𝑒𝑟 is related with the decay function. The 
parameters were initialized as follows: 𝛼𝑖𝑛 has the value 0.001, gamma has the value 0.0001, 
power has the value 0.75 and momentum has the value 0.9. In this case, the regularization is given 
by the weight decay that was initialized with the value 0.0005. The maximum iterations was 5000 
and for each 500 iterations occurs a validation test [195]. These backpropagation hyperparameters 
are stored in a file created by Caffe, called solver. These parameters are based on Godinho work 
[195] and caffe documentation.   
3.3.3 Train, Validation and Test Sets  
To train, validate and test the algorithm it was used the Monte Carlo cross-validation method 
present in the MedCNN application. This method randomly splits data into two sets: train set and 
test set Then, this process is repeated several times and several batches with one train set and one 
test set are formed. The resultant accuracy is given by the average of the accuracy of the batches 
[207].  In this case, the data is divided into three parts: the train set, the validation set and test set. 
Moreover, this method also prevents biased estimations.  
In the train set, the train data is used to optimize the function that best fits the data, for instance, 
the weight model. In the validation set, the data it is used to optimize the hypermeters such as 
number of iterations and learning rate, to estimate the error between the value predicted and the 
real value and, thus, to verify if the network does not overfits. The validation occurs during 
network training. In its turn, the test set are non-labelled and unseen data by the trained network 
that test and evaluates the network  [208].  
In this study, Monte Carlo 5-fold cross-validation was performed to obtain 5 batches for each 
classification group. It was applied an approach of splitting the data in 50% for the train set, 25% 
for the validation set and 25% for the test set. Thus, for each batch it was used a split relation of 
2:1:1 (train, validation and test).  
In this work, the group of subjects that had the less subjects was considered the limiting group 
and n corresponded to number of individuals of that group. Thus, for each classification 2n 
subjects was used which corresponds to the sum of the n subjects of the limiting group with n 
subjects random extracted from the group with more subjects.  
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In this study, it was performed the following classification: Control vs PD, Control vs SWEDD 
and PD vs SWEDD. The Table 3.2 resumes each classification group.  
Table 3.2 Characteristics of each classification group 
Groups Nº batches 
Sets* 
Train Validation Test 
Control vs PD 5 
50% (
1
2
𝑛 Control + 
1
2
𝑛 PD) 
25% (
1
4
𝑛 Control 
+ 
1
4
𝑛 PD) 
25% (
1
4
𝑛 Control 
+ 
1
4
𝑛 PD) 
Control vs SWEDD 5 
50% (
1
2
𝑛 Control + 
1
2
𝑛 SWEDD) 
25% (
1
4
𝑛 Control 
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* 𝑛 is the number of subjects of the limiting group 
The cases where this division into data sets gives non-integers numbers, the size number of the 
train and validation sets is round half down to the nearest integer and in the test set the size number 
is round half up to the nearest integer.  
To increase the information given to the network regarding regions of interest the slices were 
assembled into groups of three, as illustrated in Figure 3.5, and the average of the three slices was 
performed to produce a slice without loss of texture information as described in Savio et al. study. 
[209]. Thus, the resulting voxels are the average of the intensities of the matching pixels. The 
resulting slice is, then, the input of the CNN. The generation of slices was for all subjects. 
1 2 3 4 5 6 7 8 9 10 
11 12 13 14 15 16 17 18 19 20 
21 22 23 24 25 26 27 28 29 30 
31 32 33 34 35 36 37 38 39 40 
41 42 43 44 45 46 47 48 49 50 
51 52 53 54 55 57 57 58 59 60 
61 62 63 64 65 67 67 68 69 70 
71 72 73 74 75 77 77 78 79 --- 
Figure 3.5 Illustration of the groups of three slices that formed the 3-channel slices. 
In this case, it was only considered slices from 21 to 47 since they contain specific regions of 
interest. The slice 21 contains the beginning of the mesencephalon and the slice 47 contains the 
end of the septum pellucidum.  
To summarize, the classification was performed according to the following order:  
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1. Classification of MRI slices: 
1.1 Control vs PD 
1.2 Control vs SWEDD 
1.3 PD vs SWEDD 
2. Classification of the DaTscan slices: 
2.1 Control vs PD 
2.2 Control vs SWEDD 
2.3 PD vs SWEDD 
3.3.4 Test/ Evaluation of the Classifier CNN 
The test results are stored in a comma-separated value (.cvs) file. Thus, it is possible to analyse 
the results using statistical methods. The analysis of the test set results is based on the calculation 
of the Accuracy, the Sensitivity, the Specificity, the Positive Predictive Value (PPV) and the 
Negative Predictive Value (NPV).  
The accuracy defines the proximity of the results obtained to the real value, i.e., discrimination 
between patients from healthy subjects. The sensitivity evaluates the ability of the test to correctly 
predict if the subject has the disease and the specificity translates the capacity of the test to rightly 
predict healthy subjects.  
In its turn, the PPV defines the probability of having the disease if the test is positive and the NPV 
defines the probability of do not have the disease if the test is negative [210]. The calculation of 
those parameters was performed using the confusion matrix in Table 3.3. In this study, the 
probability of having PD or to not having PD (control group), the probability of being SWEDD 
to not having SWEDD (control group) and the probability of having PD to having SWEDD was 
compared.  
To evaluate the performance of the classifier, the Cohen’s Kappa coefficient and the Receiver 
operating characteristic (ROC) curve was used. The Cohen’s Kappa (ĸ) method measures the 
interrater reliability, that is, the agreement between two or more classifiers by taking into account 
that may occur agreement by chance. The agreement happens when two or more classifiers set 
the same score to the variables. Thus, if ĸ=1, the agreement is perfect [211]. The calculation of 
the Cohen’s Kappa is expressed in Table 3.4. 
In its turn, the ROC curve is a method that evaluates the classifier performance [212]. This curve 
is given by the plot of sensitivity vs false positive rate (FPR) that it is calculated by 1-specificity, 
as illustrated in Figure 3.6.  
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Table 3.3- Confusion matrix for the calculation of Sensitivity, Specificity and PPV and NPV. The ‘a’, ’b’, 
‘c’ and ‘d’ defines the number of subjects for each situation 
 
 Disease Not Disease  
Positive Test a  b 
 
PPV = 
𝑎
𝑎+𝑏
 
 
Negative Test c d NPV = 
𝑑
𝑐+𝑑
 
 Sensitivity = 
𝑎
𝑎+𝑐
  Specificity = 
𝑑
𝑑+𝑏
 Accuracy = 
𝑎+𝑑
𝑎+𝑏+𝑐+𝑑
 
 
Table 3.4 Calculation of Cohen’s Kappa. The a,b,c and d are the same as in the Table3.3 
Cohen’s Kappa 
𝑘 =  
𝑝𝑜 − 𝑝𝑒
1 −  𝑝𝑒
 
N = a + b + c + d 
𝑝𝑜 =
(𝑎 + 𝑏)
𝑁
 
𝑝𝑒 =  
(𝑎 + 𝑏)
𝑁
×  
(𝑎 + 𝑐)
𝑁
+  
(𝑐 + 𝑑)
𝑁
×
(𝑏 + 𝑑)
𝑁
 
 
 
 
 
 
 
 
Figure 3.6 Example of a ROC curve 
The closer is the curve to the sensitivity axes, the greater is the power of discrimination of the 
classifier. When the curve is near the chance line, it suggests that the classifier is not good at 
distinguish the two classes under testing (e.g. disease from healthy) [212].  The measure that 
translates the meaning of ROC curve is the area under the curve (AUC). AUC that analysis 
effectiveness of the classifier to distinguish disease from healthy and it based on the sensitivity 
and FPR. If AUC = 1, the classifier is perfect at performing that distinction. If AUC = 0.5, then 
the classifier is not better than change for balanced groups (i.e.groups with the same number of 
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subjects). If AUC = 0 the classifier set all the healthy subjects as unhealthy and unhealthy subjects 
as healthy [212], for example.  
In this work, the ROC curve was calculated with 95% confidence interval and it is given by the 
average of the ROC curve and AUC of the 5 batches. The standard deviation represents the 
difference between the resulting average and the batches of each imaging technique. The ROC 
curve was only performed for the slices that showed the highest accuracies. The ROC curve   and 
the AUC was performed using python. 
  
 
 
 
Chapter 4 Results 
 
4.1 Study Population 
The resulting data sample obtained after imaging pre-processing steps and respective 
demographic information of the subjects are summarized in Table 4.1. Due to noise and image 
artefacts, 18 MRI brain scans and the matching SPECT images were excluded.  
Thus, in this work, 1,208 images and 604 subjects were used. Table 4.1 shows that from the 604 
subjects, 168 were Control subjects, 338 PD patients and 58 SWEDD patients, in which each 
subject has one MRI and one SPECT images. The average age for Controls is 60 ± 11 years old, 
62 ± 8 years old for PD and for SWEDD is 62 ± 10 years old. Regarding sex, the gender ratio in 
terms of F/M was 0.54 in the Control group, 0.56 in the PD group and 0.53 in the SWEDD group. 
Table 4.1 Subjects demographic information 
 
Regarding the statistics tests performed to analyse the data sample, the results of the Mann-
Whitney U Test and Chi-square test are expressed in Table 4.2. 
Table 4.2 Test statistics results of Mann-Whitney U Test and Chi-square Test for Control, PD and SWEDD 
groups 
Groups 
Mann-Whitney U Test Chi-Square 
U p-value 𝒳2 p-value 
Control vs PD 29,884.50 0.272 0.037 0.847 
Control vs SWEDD 4,354.50 0.228 0.008 0.930 
PD vs SWEDD 10,523.00 0.623 0.049 0.825 
Group 
s N Age (yo) Sex 
(subjects) images [31,50[ [50,70[ [70,86[ Avg±std  (F/M) 
Control 168 
336 
(168 MRI + 
168 SPECT) 
27 106 35 60 ±11 59/109 
PD 378 
756 
(378 MRI + 
378 SPECT) 
40 252 86 62±10 136/242 
SWEDD 58 
116 
(58 MRI + 58 
SPECT) 
7 38 13 62 ±10 20/38 
yo.: years old; Avg: Average; std: Standard Deviation, F: Female; M: Male. 
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The p-value, regarding age comparison, was 0.272 for Control and PD groups, 0.228 for Control 
vs SWEDD, and 0.623 for PD vs SWEDD. About sex comparison the p-value was 0.847 for 
Control and PD groups, 0.930 for Control and SWEDD and 0.825 for PD and SWEDD. 
Appendix C illustrates an example of the slices MRI on Figure C.1 and DaTscan slices on Figure 
C.2 from control (healthy) subject obtained after the pre-processing steps and the images splitting, 
not including the CLAHE processing since it was just applied to slices that were used for training 
models. 
4.2 Classification  
Table 4.3 shows the number of slices that were used in the data sets of each classification of MRI 
and SPECT slices, separately taking into account order mentioned in Chapter 3.3.3.  
In Control vs PD comparison, the limiting group was the Control group that comprises 168 
subjects against the 378 PD patients. In both comparison (Control vs SWEDD and PD vs 
SWEDD), the limiting group was the SWEDD group which comprises 58 slices.  
As can be seen on Table 4.3, the train set comprises 168 slices in Control vs PD and 58 slices in 
the other comparisons, which is 50% of the total of slices used in each case. Each validation and 
tests set comprise 84 slices in Control vs PD, 14 slices and 15 slices, respectively, in Control vs 
SWEDD and PD vs SWEDD. 
Table 4.3 Number of slices used for each classification group in Train, Validation and Test 
Classification 
Group 
Total slices used Train Validation Test 
Control vs PD 
 
336 
(168 Control/ 168 PD) 
84 Control 
84 PD 
42 Control 
42 PD 
 42 Control 
42 PD 
Control vs 
SWEDD 
 
116 
(58 Control/ 58 SWEDD) 
29 Control 
29 SWEDD 
14 Control 
14 SWEDD 
15 Control 
15 SWEDD 
PD vs SWEDD 
116 
(58 PD/ 58 SWEDD) 
29 PD 
29 SWEDD 
14 PD 
14 SWEDD 
15 PD 
15 SWEDD 
 
The slices that encompass regions of interest, namely, mesencephalon and basal ganglia, are 
illustrated in Figure 4.1. 
4.1.1 Comparison of Control and Parkinson’s Disease 
The accuracy results obtained in the comparison of Control and PD subjects using MRI images 
for each batch are expressed in Table B.1 and using SPECT images are in Table B.2 of 
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Appendix B. These tables show that the slices that lead to the highest accuracy were MRI 
slices 27_28_29 and SPECT slices 39_40_41.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Slices that comprises the mesencephalon and the basal ganglia. These slices are from a Control 
subject, PD patient and a SWEDD patient. 
Figure 4.2 shows the average accuracy of the five batches achieved with MRI and SPECT slices. 
As is shown in that figure, the CNN was able to distinguish Control from PD with 97.4±1.2% 
average accuracy using MRI slices 27_28_29 that encompassing the mesencephalon. This result 
was the highest in the distinction of PD from Control within the MRI and SPECT results, followed 
by SPECT slices 39_40_41 comprising the basal ganglia that had 92.4±3.6% average accuracy. 
Unlike MRI slices 27_28_29, the matching SPECT slices had a lower accuracy 62.0±2.5%. MRI 
slices 39_40_41 had also a small average accuracy 45.7±2.9 %. The remain MRI slices showed 
an accuracy approximately to 50% as SPECT slices 21_22_23 and SPECT slices 24_25_26. From 
SPECT slices 30_31_32 to slices 45_46_47 the average accuracy was always above 73%. 
Mesencephalon - Control Basal Ganglia - Control 
Mesencephalon - PD Basal Ganglia - PD 
Mesencephalon – SWEDD Basal Ganglia – SWEDD 
MRI SPECT MRI SPECT 
Slices 27_28_29 Slices 39_40_41 
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Figure 4.2 Average accuracy using MRI and SPECT slices in Control vs PD 
 
 Figure 4.3 Accuracy results for Mesencephalon MRI vs SPECT in Control vs PD 
Figure 4.3 illustrates the accuracy of the five batches resulting from the cross-validation of MRI 
and SPECT slices 27_28_29 that include the mesencephalon. This figure shows that the highest 
accuracy result achieved was 98.8% in batch 5 using MRI slices. The accuracy concerning SPECT 
slices 27_28_29 was close to 60% in all batches. 
Regarding the accuracy obtained using slices 39_40_41 encompassing the basal ganglia, those 
results are illustrated in Figure 4.4. The highest accuracy in was 97.6% in Batch 2 and the lower 
was 88.1% using Batch 5 using SPECT slices. The other SPECT batches had similar results, 
unlike MRI batches that presented an accuracy close to 45%.  
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Figure 4.4 Accuracy results for Basal Ganglia - MRI vs SPECT in Control vs PD 
 
Table 4.4 Sensitivity, Specificity, PPV, NPV and Cohen's Kappa for Control vs PD using MRI and 
SPECT images 
The results of Sensitivity, Specificity, PPV, NPV, and Kappa of MRI and SPECT slices of the 
classification, are summarized in Table 4.4. The higher specificity and sensitivity results were 
100.0% and 94.76% respectively, obtained with MRI slices 27_28_29.  
Slices 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Kappa + std  
Slices 21_22_23 
MRI 51.43 55.24 53.55 53.14 0.07±0.11 
SPECT 59.05 59.52 59.61 59.09 0.19±0.11 
Slices 24_25_26 
MRI 50.95 50.48 50.02 51.56 0.01±0.11 
SPECT 55.71 62.86 60.04 58.96 0.19±0.11 
Slices 27_28_29 
MRI 100.00 94.76 95.07 100.00 0.95±0.03 
SPECT 62.38 61.43 61.82 62.23 0.24±0.11 
Slices 30_31_32 
MRI 54.29 58.57 56.05 57.01 0.13±0.11 
SPECT 74.29 76.19 76.82 74.76 0.50±0.09 
Slices 33_34_35 
MRI 53.81 50.48 52.15 52.16 0.04±0.11 
SPECT 82.38 74.76 77.03 80.81 0.57±0.09 
Slices 36_37_38 
MRI 49.05 56.19 52.49 52.76 0.05±0.11 
SPECT 89.05 89.52 89.81 89.34 0.79±0.07 
Slices 39_40_41 
MRI 48.10 43.33 45.84 45.45 -0.09±0.11 
SPECT 92.86 91.90 92.11 92.81 0.85±0.06 
Slices 42_43_44 
MRI 44.76 47.14 45.80 46.09 -0.08±0.11 
SPECT 81.90 89.05 88.42 83.35 0.71±0.08 
Slices 45_46_47 
MRI 48.10 51.90 50.14 49.88 0.00±0.11 
SPECT 75.24 71.90 73.03 74.64 0.47±0.10 
std: Standard Deviation 
48.8%
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Unlike MRI, the matching SPECT slices had 62.38% sensitivity and 61.43% specificity. SPECT 
slices 39_40_41 achieved 92.86% sensitivity and 91.90% specificity, and the matching MRI 
slices had 48.10% sensitivity and 43.33% specificity.  
Figure 4.4 also shows that the PPV and NPV was 95.07% and 100.0%, respectively, in MRI slices 
27_28_29, and 92.11% and 92.81% in SPECT slices 39_40_41. Regarding the Cohen’s Kappa, 
MRI slices 27_28_29 achieved ĸ = 0.95±0.03 which is higher than the result of SPECT slices 
39_40_41 that was ĸ = 0.85±0.06. 
The ROC curve and the respective AUC of the mesencephalon and basal ganglia are illustrated 
in Figure 4.5 and Figure 4.6, respectively. Figure 4.5 shows that the AUC was higher using MRI 
slices since these slices presented AUC = 0.99, CI 95%: [0.96 - 1.00] using MRI slices of the 
mesencephalon.  
 
 
 
 
 
 
 
 
 
Figure 4.5 ROC curve and AUC for PD in mesencephalon classification of Control vs PD. 
Regarding slices encompassing the basal ganglia, Figure 4.6 shows that the AUC was 0.98, CI 
95%: [0.94 - 1.00] using SPECT slices which is higher than the results obtained using the 
matching MRI slices.  
Figure 4.7 expresses the confusion matrixes of the batches with higher accuracy of the 
classification of the mesencephalon. The confusion matrix of the batch 5 of the classification 
using MRI slices shows that the CNN was able to correctly predict 100% of the PD patients and 
97.62% of the Controls subjects. The CNN using SPECT slices of the batch 5 was able to correctly 
classify 61.90% of the PD-patients and 66.67% of the Control Subjects. 
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Figure 4.6 ROC curve and AUC for PD in basal ganglia classification of Control vs PD. 
 
                                                       
 
 
 
 
 
 
 
 
 
Figure 4.7 Confusion matrix of MRI slices of the batch 5 and SPECT slices of the batch 5. These slices 
comprise the mesencephalon (Slices 27_28_29). 
Regarding the classification of the basal ganglia, Figure 4.8 shows the predictions of the 
classification using MRI and SPECT slices 39_40_41.  
The CNN, using MRI slices of the Batch 2, was able to rightly predict 45.24% of the PD patients 
and 35.72% of the Controls. These results were lower than those achieved by the classification 
using SPECT slices. With SPECT slices, the CNN was able to predict 95.24% of the PD patients 
and 95.24% of the Control subjects. 
 
Batch 5 Real Class  
Predicted Class PD Control  
PD 42 1 43 
Control 0 41 41 
 42 42 N = 84 
Batch 5 Real Class  
Predicted Class PD Control  
PD 26 14 40 
Control 16 28 44 
 42 42 N = 84 
Confusion matrix of MRI slices - Mesencephalon 
Confusion matrix of SPECT slices - Mesencephalon 
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Figure 4.8 Confusion matrix of MRI sliced of the batch 2 and SPECT slices of the batch 1. These slices 
correspond to the basal ganglia (slices 39_40_41). 
 
4.2.2 Comparison of Control and SWEDD 
The accuracy results of the classification of Control vs SWEDD are expressed in Table B.3 and 
Table B.4 for MRI slices and in Table 4.8 for SPECT slices, respectively, in Appendix B. Those 
tables show that the accuracy results of MRI and SPECT slices are similar.  
As can be seen in Figure 4.9, the results of the average accuracy of the MRI slices were slightly 
higher than those achieved using SPECT slices.  
 
Figure 4.9 Average Accuracy for MRI and SPECT Control vs SWEDD 
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For instance, both MRI and SPECT slices that encompass the mesencephalon had 54.7% average 
accuracy. Regarding the slices that comprise the basal ganglia, SPECT slices 39_40_41 had 
62.7% average accuracy and the matching MRI slices had 52.0%.  
Figure 4.10 and Figure 4.11 show the resulting accuracy of the classification of Control vs 
SWEDD using MRI and SPECT slices comprising regions of interest. 
Figure 4.10 illustrates that the batches have distinct results in both medical imaging techniques. 
For instance, MRI slices had 50.0% accuracy in Batch 1 and 73.33% in Batch 2. The same 
occurred with SPECT slides, e.g., Batch 1 presented 40.0% accuracy and Batch 5 had 70.00%. 
Figure 4.10 Accuracy results of Mesencephalon classification - MRI vs SPECT in Control vs SWEDD 
 
Figure 4.11 Accuracy results of Mesencephalon classification - MRI vs SPECT in Control vs SWEDD 
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Regarding the basal ganglia slices, Figure 4.13 shows that the batches in the classification with 
MRI slices have an accuracy between 60.00% and 73.33%. Concerning SPECT batches, those 
have an accuracy between 53.33% and 80.00%. As in the previous case of the mesencephalon 
classification, the results are similar.  
The Table 4.9 expresses the Sensitivity, Specificity, PPV, NPV and Cohen’s Kappa obtained in 
Control vs SWEDD classification.  
Table 4.5 Sensitivity, Specificity, PPV, NPV and Cohen's Kappa for Control vs SWEDD using MRI and SPECT images 
Slices 
 Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Kappa ± Std 
Slices 21_22_23 
MRI 44.00 72.00 62.65 55.94 0.16±0.18 
SPECT 58.67 60.00 59.31 60.04 0.19±0.18 
Slices 24_25_26 
MRI 66.67 64.00 66.01 66.29 0.31±0.17 
SPECT 54.67 64.00 60.08 58.80 0.19±0.18 
Slices 27_28_29 
MRI 58.67 50.67 54.66 54.66 0.09±0.18 
SPECT 49.33 60.00 56.13 53.92 0.09±0.18 
Slices 30_31_32 
MRI 49.33 58.67 55.25 53.44 0.08±0.18 
SPECT 48.00 44.00 46.01 45.83 -0.08±0.18 
Slices 33_34_35 
MRI 58.67 53.33 55.10 57.20 0.12±0.18 
SPECT 53.33 49.33 52.67 47.54 0.03±0.18 
Slices 36_37_38 
MRI 53.33 57.33 57.39 54.75 0.11±0.18 
SPECT 53.33 44.00 50.20 46.55 -0.03±0.18 
Slices 39_40_41 
MRI 65.33 65.33 65.34 65.81 0.31±0.17 
SPECT 68.00 57.33 62.81 63.33 0.25±0.17 
Slices 42_43_44 
MRI 49.33 64.00 58.87 56.07 0.13±0.18 
SPECT 50.67 49.33 52.62 48.77 0.00±0.18 
Slices 45_46_47 
MRI 66.67 60.00 62.86 64.92 0.27±0.17 
SPECT 54.67 49.33 51.19 52.27 0.04±0.18 
Std: standard deviation 
As show in Table 4.5, MRI slices 27_28_29 had 58.67% sensitivity, 50.67% specificity, 54.66% 
PPV and 54.66 NPV and SPECT slices 39_40_41 had 68.00% sensitivity, 57.33% specificity, 
62.81% PPV and 63.33 NPV. Regarding Cohen’s Kappa, MRI slices encompassing the 
mesencephalon and the matching SPECT slices had both ĸ = 0.09±0.18. SPECT slices 39_40_41 
presented ĸ = 0.25±0.17 and the matching MRI slices had ĸ = 0.31±0.17. 
Concerning the ROC curve and the respective AUC, the results of AUC achieved using slices 
comprising the mesencephalon and the basal ganglia are illustrated in Figure 4.12 and Figure 
4.13, respectively. In the classification of the Control vs SWEDD, Figure 4.12 shows that MRI 
slices encompassing the mesencephalon had AUC = 0.57 with CI 95% [0.36-0.78] and SPECT 
slices had AUC = 0.54 with CI 95% [0.33-0.75] and these results are close to the chance level. 
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Figure 4.12 ROC curve and AUC obtained in the classification of mesencephalon slices, in Control vs 
SWEDD 
As it is shown in Figure 4.13, the AUC was 0.67 with CI 95% [0.48-0.87] using MRI slices and 
0.66 with CI 95% [0.46-0.85] using SPECT slices.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 ROC curve and AUC obtained in the classification of basal ganglia slices, in Control vs 
SWEDD 
The confusion matrixes of the classification of Control and SWEDD using MRI and SPECT slices 
comprising regions of interest are expressed in Figure 4.14 and Figure 4.15. 
Figure 4.14 shows that CNN using MRI slices 27_28_29 of Batch 2 was able to predict 66.67% 
of the SWEDD patients and 60% of the Controls and SPECT slices of Batch 5 correctly predict 
80% of the SWEDD cases and 80% of the healthy subjects. It is important to notice that these 
were the batches that presented the highest accuracy. 
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In its turn, Figure 4.15 shows that using MRI slices comprising the basal ganglia, the CNN was 
able to correctly predict 73.33% of the SWEDD cases and 73.33% of the Controls.  
Regarding SPECT slices, the CNN correctly classified 80% of the SWEDD patients and 80% of 
the healthy subjects. 
                                                       
 
 
 
 
 
 
 
 
 
 
 
                                   
 
 
 
 
 
 
 
 
 
Figure 4.15 Confusion matrix of MRI slices of the batch 5 and SPECT slices of the batch 5. These slices 
correspond to basal ganglia (Slices 39_40_41). 
 
Batch 2 Real Class  
Predicted Class SWEDD Control  
SWEDD 10 6 16 
Control 5 9 14 
 15 15 N = 30 
Batch 5 Real Class  
Predicted Class SWEDD Control  
SWEDD 12 3 15 
Control 3 12 15 
 15 15 N = 30 
Figure 4.14 Confusion matrix of MRI slices of the batch 2 and SPECT slices of the batch 5. These slices 
correspond to the mesencephalon (Slices 27_28_29). 
 
 
 
 
 
Batch 5 Real Class  
Predicted Class SWEDD Control  
SWEDD 11 4 15 
Control 4 11 15 
 15 15 N = 30 
Batch 5 Real Class  
Predicted Class SWEDD Control  
SWEDD 12 3 15 
Control 3 12 15 
 15 15 N = 30 
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Confusion matrix of SPECT slices - Mesencephalon 
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4.2.3 Comparison of Parkinson’s Disease and SWEDD 
The accuracy results achieved in the classification of PD vs SWEDD using MRI slices are in 
Table B.5 and using SPECT slices are in Table B.6 in the Appendix B. These results show that 
the highest accuracy was obtained using MRI slices 27_28_29, SPECT slices 36_37_38 and 
SPECT slices 39_40_41. The accuracy of these slices is expressed in the following figures.  
For instance, Figure 4.16 shows the average accuracy obtained with all the slices considered in 
this work. As can be seen in Figure 4.16, the highest average accuracy was achieved using SPECT 
slices 36_37_38 which presented 93.3±3.7%, followed by Slices 39_40_41 comprising the basal 
ganglia that achieved 86.0±4.9%. Concerning MRI slices including the mesencephalon, these 
obtained 73.3±3.7% average accuracy. The remaining MRI slices had average accuracy results in 
a range of 51.3% to 69.3% and SPECT slices between 48.7% and 80.0%. 
 
Figure 4.16 Average Accuracy for MRI and SPECT PD vs SWEDD 
In the classification of PD vs SWEDD, using MRI slices 27_28_29, the CNN achieved 76.7% 
accuracy in batches 2 and 4, and 73.3% accuracy in batches 3 and 5, as shown in Figure 4.17. 
Unlike MRI, Figure 4.17 also shows that the accuracy of the matching SPECT slices was 66.67% 
in batch 4, 63.3% in batch 3 and 60.0% in batches 2 and 5. 
Regarding the classification using slices that encompasses the basal ganglia, Figure 4.18 shows 
that using SPECT slices, the batch with the highest accuracy was the batch 1 with 93.3% accuracy, 
followed by the batch 3 that presented 90.0% accuracy. Regarding MRI slices, these presented 
approximately 56% accuracy.  
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The slices that presented higher accuracy, the results of the batches are displayed on Figure 4.19. 
SPECT slices 36_37_38 achieved 96.7% accuracy in batches 1 and 3 and 86.7% accuracy in batch 
4 which is the lower result of these slices. Unlike SPECT, the accuracy of the matching slices was 
close to 60%.  
 
Figure 4.17 Accuracy results of Mesencephalon classification - MRI vs SPECT in PD vs SWEDD 
 
Figure 4.18  Accuracy results of Basal Ganglia classification - MRI vs SPECT in PD vs SWEDD 
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Figure 4.19 Accuracy results of slices 36_37_38 classification - MRI vs SPECT in PD vs SWEDD 
The results of Sensitivity, Specificity, PPV, NPV and Cohen’s Kappa are summarized in Table 
4.12. The distinction of PD vs SWEDD using MRI slices encompassing the mesencephalon 
(Slices 27_28_29) showed 65.33% sensitivity, 81.33% specificity, 79.01% PPV, 70.88% NPV. 
Table 4.6 Sensitivity, Specificity, PPV, NPV and Cohen's Kappa for PD vs SWEDD using MRI and SPECT 
slices 
 
Slices  
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Kappa ± 
Standard 
error 
Slices 21_22_23 MRI 50.67 52.00 51.36 51.20 0.03±0.18 
 SPECT 50.67 46.67 47.96 50.28 -0.03±0.18 
Slices 24_25_26 MRI 73.33 65.33 68.71 70.36 0.39±0.16 
 SPECT 57.33 48.00 52.92 52.54 0.05±0.18 
Slices 27_28_29 MRI 65.33 81.33 79.01 70.88 0.47±0.16 
 SPECT 58.67 50.67 54.66 54.66 0.09±0.18 
Slices 30_31_32 MRI 60.00 56.00 58.10 57.89 0.16±0.18 
 SPECT 61.33 62.67 62.30 62.09 0.24±0.18 
Slices 33_34_35 MRI 65.33 58.67 60.90 63.65 0.24±0.18 
 SPECT 74.67 85.33 84.59 78.33 0.60±0.14 
Slices 36_37_38 MRI 69.33 50.67 59.44 63.24 0.20±0.18 
 SPECT 96.00 90.67 91.53 95.88 0.87±0.09 
Slices 39_40_41 MRI 56.00 53.33 54.83 55.45 0.09±0.18 
 SPECT 86.67 85.33 85.74 86.45 0.72±0.12 
Slices 42_43_44 MRI 65.33 48.00 55.76 58.43 0.13±0.18 
 SPECT 74.67 77.33 79.60 75.10 0.52±0.15 
Slices 45_46_47 MRI 62.67 52.00 56.44 58.67 0.15±0.18 
 SPECT 76.00 65.33 67.80 75.91 0.41±0.16 
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SPECT slices 27_28_29 had 58.67% sensitivity, 50.67% specificity. Regarding the slices that 
comprise the basal ganglia, the CNN achieved 86.87% sensitivity and 85.33% specificity using 
SPECT slices 38_40_41. The slices with higher accuracy, slices 36_37_38, presented 96% 
sensitivity, 90.67% specificity, 91.53% PPV and 95.88% NPV. 
Concerning the Cohen’s Kappa obtained in the comparison of PD and SWEDD, MRI slices 
27_28_29 had ĸ = 0.47±0.16, SPECT slices 39_40_41 had ĸ = 0.72±0.12. SPECT slices 
36_37_38 showed presented the highest ĸ (0.87±0.09).  
 
The results of the ROC curve to the classification PD vs SWEDD of the slices 27_28_29, slices 
36_37_38 and slices 39_40_41 are in Figure 4.20, Figure 4.21 and Figure 4.22, respectively.  
 
 
 
 
 
 
 
 
 
 
Figure 4.20 ROC curve and AUC obtained in the classification of mesencephalon slices, in PD vs SWEDD 
 
 
 
 
 
 
 
 
 
 
Figure 4.21 ROC curve and AUC obtained in the classification of slices 36_37_38, in PD vs SWEDD. 
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The classification of PD vs SWEDD using MRI slices including the mesencephalon had AUC = 
0.84 [0.69 – 0.98] with CI of 95%. In its turn, SPECT slices presented AUC = 0.61 [0.40 – 0.81] 
with CI of 95%, as illustrated in Figure 4.22.  
Regarding the slices of the basal ganglia, the ROC curves of MRI and SPECT slices are 
represented in Figure 4.21. In its turn, SPECT slices presented AUC = 0.90 [0.79 – 1.00] with CI 
of 95%, and a standard deviation of 0.05. 
Figure 4.22 shows the ROC curves and respective AUC of MRI and SPECT slices 36_37_38. In 
this case, MRI slices showed AUC = 0.63 [0.43 – 0.83] with CI of 95%, SPECT slices presented 
AUC = 0.98 [0.92 – 1.00] with CI of 95%, and a standard deviation of 0.01. 
 
 
 
 
 
 
 
 
Figure 4.22 ROC curve and AUC obtained in the classification of basal ganglia slices, in PD vs SWEDD. 
                                                      
 
 
 
 
 
 
 
Figure 4.23 Confusion matrix of the MRI and SPECT slices of the batch 2. These slices correspond to the 
mesencephalon (Slices 27_28_29). 
Batch 2 Real Class  
Predicted Class SWEDD PD  
SWEDD 9 1 10 
PD 6 14 14 
 15 15 N = 30 
Batch 2 Real Class  
Predicted Class SWEDD PD  
SWEDD 8 5 13 
PD 7 10 17 
 15 15 N = 30 
Confusion matrix of MRI slices - Mesencephalon 
Confusion matrix of SPECT slices - Mesencephalon 
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Figure 4.23 contains the confusion matrixes of MRI and SPECT slices 27_28 _29 of the batch 2. 
The CNN classifier using MRI slices was able to correctly predict 60% of the PD cases and 
93.33% of the Control subjects.  
Using MRI slices 39_40_41 encompassing the basal ganglia, the CNN was able to correctly 
predict, in batch 5, 80% of the PD patients and 40% of the Control subjects, as illustrated in Figure 
2.24. Unlike MRI, using the matching SPECT slices of PD, the algorithm was able to predict 
100% of the PD cases and 93.33% of the Controls.   
                                           
 
 
 
 
 
 
 
Figure 4.24 Confusion matrix of the MRI and SPECT slices of the batch 5. These slices correspond to basal 
ganglia (slices 39_40_41). 
                                                
 
 
 
 
 
 
 
Figure 4.25 Confusion matrix of the MRI and SPECT slices of the batch 3. These slices correspond to slices 
36_37_38. 
 
 
Batch 5 Real Class  
Predicted Class SWEDD PD  
SWEDD 13 6 19 
PD 2 9 11 
 15 15 N = 30 
Batch 5 Real Class  
Predicted Class SWEDD PD  
SWEDD 12 3 15 
PD 3 12 15 
 15 15 N = 30 
Batch 3 Real Class  
Predicted Class SWEDD PD  
SWEDD 12 9 21 
PD 3 6 6 
 15 15 N = 30 
Batch 3 Real Class  
Predicted Class SWEDD PD  
SWEDD 15 1 16 
PD 0 14 14 
 15 15 N = 30 
Confusion matrix of MRI slices – Basal Ganglia 
Confusion matrix of SPECT slices – Basal Ganglia 
Confusion matrix of MRI slices – Slices 36_37_38 
Confusion matrix of SPECT slices – Slices 36_37_38 
  
 
 
 
As it is shown it Figure 4.25, using SPECT slices 36_37_38, the CNN was able to correctly 
classify 80% of the PD cases and 80% of the Controls subjects unlike using MRI slices that rightly 
predict 86.67% of the PD patients and 86.67% of the Controls.  
  
 
 
 
Chapter 5 Discussion 
 
5.1 Main results 
The main and most significant results obtained in this dissertation are following enumerated:  
a) The discrimination of Control from PD: 
• Using MRI slices 28_29_30 encompassing the mesencephalon, the CNN 
achieved 97.4% average accuracy, which were the highest accuracy result in this 
classification, and AUC = 0.99  
• Using SPECT slices 39_40_41 encompassing the basal ganglia, the CNN 
obtained 92.4% average accuracy and AUC = 0.98 
b) The discrimination of Control from SWEDD: 
• MRI and SPECT slices had similar results, for instance, approximately 50-60% 
accuracy 
c) The discrimination of PD from SWEDD: 
• Using MRI slices 28_29_30 encompassing the mesencephalon, the CNN 
achieved 73.3% average accuracy and AUC = 0.84 
• Using SPECT slices 39_40_41 encompassing the basal ganglia, the CNN 
obtained 86.0% and AUC = 0.90 
• Using SPECT slices 36_37_38, the CNN achieved 93.3% average accuracy and 
AUC = 0.98 
5.2 Classification 
Prior to the classification, the Mann-Whitney test and Chi-Square were performed. The Mann-
Whitney results showed that there are no had no significant differences in terms of age between 
the subjects of the following groups: Control and PD (p = 0.272), Control and SWEDD (p = 
0.228), and PD and SWEDD (p = 0.623). In its turn, the Chi-Squared showed that there is no 
significant association between the sex of the subjects that comprises these groups: Control and 
PD (p = 0.847), Control and SWEDD (p = 0.930), and PD and SWEDD (p = 0.825). 
Taking into account these results, the data sample used in Control vs PD, in Control vs SWEDD, 
and in PD vs SWEDD was considered age and sex-matched as well as the groups of subjects 
present in each test set used in the classification.  
Concerning the classification of Control vs PD, the CNN classifier was able to distinguish PD 
from healthy subjects using MRI slices that encompassed the mesencephalon and using SPECT 
slices comprising the basal ganglia. Moreover, these MRI slices lead to higher accuracy in the 
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classification of PD and Control. For instance, MRI slices embracing the mesencephalon 
presented higher average accuracy (97.4%) than the matching SPECT slices (61.70%) and SPECT 
slices including the basal ganglia presented also higher accuracy (92.4%) than the same MRI 
slices (41.75%).  The results also showed that in the classification using SPECT slices, the CNN 
tend to present higher accuracy when slices containing the basal ganglia or structures near it are 
used. Unlike SPECT, the accuracy of the classifier using the matching MRI slices tends to 
decrease to 45-50% in slices including the basal ganglia or other structures than mesencephalon.  
Concerning Cohen’s Kappa results, the kappa of the MRI slices encompassing the mesencephalon 
was 0.95±0.03 which, according to McHugh, is an almost perfect level of agreement [213] with 
the real PPMI label. In its turn, SPECT slices including the basal ganglia showed a strong level 
of accordance (ĸ = 0.85±0.06) [213] with PPMI database. The SPECT slices, containing structures 
anatomically located close to the basal ganglia, presented a moderate level of agreement with the 
PPMI labels (0.60 < ĸ < 0.80). The classification with the remaining slices presented a weak level 
of agreement (ĸ < 0.50) [213] with the medical diagnosis of PPMI.  
Moreover, the analysis of the ROC curve shows that using MRI slices 27_28_29 and SPECT 
slices 39_40_41 the classifier had an outstanding ability to discriminate PD from Controls [214], 
according to Hosmer and Lemeshow, presenting AUC = 0.99 and AUC = 0.98, respectively. 
Unlike these slices, the AUC of the SPECT slices 27_28_29 and MRI slices 39_40_41 shows that 
the CNN was not able to discriminate PD from Control.  
Concerning the anatomically and physiologically point-of-view, the classification of PD and 
Control show that the slices that achieved higher accuracy and AUC were those that comprise the 
mesencephalon or the basal ganglia, which are, according to the literature, regions of interest in 
PD [1]. Moreover, the results of the MRI slices 27_28_29 classification are in accordance with 
the studies conducted by Minati et al. and Kwon et al. which suggest that substantia nigra of PD 
suffer changes that are detectable by MRI [89], [90]. Regarding the results of the SPECT slices 
39_40_41 classification, these are in accordance with the literature that suggests that PD patients 
had alterations in the basal ganglia due to the dopaminergic deficit [1], [3] that it is detected using 
DaTscan SPECT scans [123]. 
In Table 5.1 it is shown the results obtained in this work in comparison with those achieved by 
other studies. For instance, the study conducted by Esmaeilzadeh et al. presented 100% accuracy 
in the classification of PD and Control using 3D MRI images [22], which is a higher value than 
the accuracy obtained using the MRI slices encompassing the mesencephalon (97.4%). However, 
it is important to note that in the study of Esmaeilzadeh et al., there is no explicit information 
either if the authors performed more than one test or if they used cross-validation methods as used 
in this work.  
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Table 5.1 Comparison of studies that performed classification of Control vs PD  
Authors Control vs PD (test sets results*) 
Acc 
(%) 
Sen 
(%) 
Spe 
(%) 
AUC 
(%) 
Esmaeilzadeh 
et al [22] 
- MRI 3D images 
- Datasets: (85%,10%,5%) 
Train set: 1040 images; Validation set: 120 
images; Test set: 56 images  
- Subjects: 
452 PD:  
292M Age: 63.3±9.8 years old 
160F, Age: 61.9±9.9 years old 
204 Control: 
134M, Age: 61.7±10.9 years old 
70F, Age: 59.2±11.6 years old 
- Data Augmentation 
- Algorithm:  
 3D CNN + Dropout + group normalization 
+ Demographic information about the 
subjects (age and sex) 
100 NA NA 1.00 
Singh et al. 
[169] 
MRI images 
- Subjects: 
518 PD:  
346M/172F, Age: 61.8±9.6 years old 
245 Control: 
155M, 90F, Age: 60.1±11.4 years old 
- Algorithms:  
SOM for Feature Extraction  
(features: intensity) 
LSSVM for training and classification 
(10 folds) 
It was performed two cases: 
    
1. Age Unrelated Groups 87.4 71.9 94.7 NA 
       2.    Age Related Groups 97.2 93.4 98.9 NA 
Amoroso et al. 
[215] 
MRI images 
- Datasets: 
NA 
- Subjects: 
374 PD:  
243M/131F, Age: 61.6±9.8 years old 
 169 Control: 
93.0 93.0 92.0 0.92 
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107M, 62F, Age: 60±11.5 years old 
- Algorithms:  
Random Forest for Feature Extraction 
(features: connectivity measures + clinical 
data) 
SVM for classification 
(10 fold-cross validation) 
Choi et al. 
[25] 
SPECT DaTscan 3D images 
- Subjects: 
374 PD:  
245M/134F, Age: 61.5±9.9 years old 
170 Control: 
112M, 58F, Age: 60.9±11.5 years old 
- Data Sets: 
Train/Validation sets: 
379 PD/ 170 Control 
Test set: 
52 PD/ 23 NC 
- Algorithms:  
1.   3D CNN 96.0 94.2 100 0.988 
2.   Visual interpretation 87.4 97.2 65.2 0.81 
3. Visual interpretation + conventional 
quantification (regional DaT binding ratio of 
putamen/ caudate and occipital cortex) 
92.0 96.2 82.6 0.92 
Oliveira et 
al.[21] 
SPECT DaTscan 3D images 
- Subjects: 
445 PD:  
287M/158F, Age: 61.6±9.8 years old 
209 Control: 
136M, 73F, Age: 61.8±1135 years old 
- Algorithms:  
SVM 
Input of SVM: 
Features that contains the Binding potential 
ratio of Striatal VOIs with cortex and 
occipital reference VOIs 
(20-fold cross-validation) 
97.86 97.75 98.09 NA 
Martinez-
Murcia et al. 
[153] 
SPECT DaTscan 3D images 
- Subjects: 
158 PD  
95.5 96.1 94.5 NA 
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111 Control 
- Data Augmentation 
- Algorithms:  
3D CNN 
CNN input: portions of the images 
containing the striatum 
(10-fold cross validation) 
The present 
study 
MRI and SPECT slices  
- Datasets: 
2:1:1 - train, validation and test 
Train set: 84 PD/ 84 Control 
Validation set: 42 PD/ 42 Control 
Test set: 42 PD/ 42 Control 
- Subjects: 
378 PD 
242M, 136F, Age: 62.0±10.0 
168 Control 
109M, 59F, Age: 60.0±11.0 years old 
- Algorithms:  
2D CNN 
(5 batches: Monte Carlo cross-validation) 
2 cases: 
MRI mesencephalon slices 97.4 100.0 94.8 0.99 
SPECT basal ganglia slices  92.4 92.8 91.9 0.98 
Acc: Accuracy, Sen: Sensitivity, Spe: Specificity; AUC: Area Under the Curve; VOIs: Voxels of interest, Age 
is mean ±standard deviation. M: Male; F: Female.  
Furthermore, the present work used balanced datasets to prevent biased results unlike the study 
mentioned above that did not specified if the datasets contains the same number of PD and 
Controls subjects. A drawback of this work in comparison with the study of Esmaeilzadeh et al. 
is the fact that the size of the train set is smaller than the 1040 images used in the 3D CNN. These 
images were obtained using data augmentation - flip technique [22] - and in this work these 
techniques were not applied. 
Although the CNN was capable of classifying PD and Controls using MRI slices 27_28_29, this 
classifier was not able to discriminate those groups using the MRI slices 39_40_41 comprise the 
basal ganglia. This fact does not agree with the classifier in the study of Esmaeilzadeh et al. and 
the SOM algorithm in Singh et al. study that considered this region as an important feature for 
the classification [22] when MRI images are used. However, these supports the evidence of 
changes in PD SPECT slices 39_40_41. 
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As it is shown in Table 5.1, unlike this work, the study conducted by Singh et al. used a Feature 
Extraction algorithm. In this case, the SOM algorithm extract features based on the variations in 
the intensity of the PD images in comparison with Controls as well as differences between voxels 
[187] to create a vector with regions of interest. 
 In the comparison of Control vs PD, the present work achieved higher accuracy than the 
classification using the group of Age Unrelated Groups (AUG) (87.4%) in the Singh et al. study. 
In the classification of AUG, the authors extracted as features the variations in the intensity of the 
grey matter images, white matter images and original images [169]. Moreover, the PPV (95.07%) 
and NPV (100.0%) were also higher in this study in comparison with Singh et al. (PPV = 87.5 
and NPV = 86.5) [169]. In the classification of the Age-Related Groups (ARG), the features were 
extracted from the difference in the average intensity in each age group. In comparison with this 
case, the CNN using MRI slices 27_28_29 presented the same accuracy result as the SVM 
classifier. However, the specificity is lower and differ in approximately 4% but has higher 
sensitivity. In this study, the NPV was higher but the PPV was lower comparatively with the that 
study (NPV = 97.3% and PPV = 97.2%) [169]. It is also important to notice that the Singh et al. 
used an unbalance sample (245 Controls and 518 PD patients), unlike this work, which may lead 
to biased results.  
In comparison with Amoroso et al. study, the CNN using MRI slices 27_28_29 presented higher 
accuracy (97.4%) and AUC (0.99), as shown in Table 5.1. Although the number of batches used 
in that study is higher (10 fold-cross validation), they used an unbalanced data set (169 Controls 
and 374 PD patients) that may influence the results.  
The present study uses CNN to extract characteristics such as the textures of the input image in 
contrast to the Amoroso et al. study that uses Random Forests to extract features based on 
connectivity measures [215]. These connectivity measures using the Pearson’s correlation were 
obtained from a network model of the brain regions based on T1-W 3D MRI images [215]. The 
present work considered the mesencephalon and the basal ganglia as important regions of interest 
unlike the  Random Forests that considered the frontal, occipital and temporal [215] as 
signification regions and gave less importance to the mesencephalon. 
The classification using the SPECT slices of the basal ganglia obtained a slightly lower accuracy 
test (92.4%) than the accuracy achieved by Choi et al. (96.0%) using 3D CNN [25], Martinez-
Murcia et al. (95.5%) [151] and Oliveira et al. (97.86%) [21]. However, the same SPECT slices 
present higher accuracy and Cohen’s Kappa (ĸ = 0.85±0.06) than the accuracy of the visual 
interpretation by experts and by the conventional techniques calculated in Choi et al. study (ĸ = 
0.65±0.11) [21].  
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In comparison with the results of the MRI slices contains the mesencephalon, these achieved 
higher accuracy and sensitivity than the studies mentioned in Table 5.1 concerning classification 
if Control and PD using SPECT but lower specificity (94.8%)  in comparison with Oliveira et al. 
study (98.09%) [21]. However, it is also important to notice that although Oliveira et al. and 
Martinez-Murcia et al. studies used cross-validation methods, the data sample used in the 
classification is unbalance, since the number of PD patients is higher than the number of Controls 
subjects.  
In this study, the features were extracted from the entire SPECT slices. However, instead of all 
image, Martinez-Murcia et al. used only portions of the image that contained volumes of interest 
(VOIs), namely the striatum, which obliges the use of another pre-processing step for 
segmentation. Despite this difference, the accuracy results in comparison with this study just had 
approximately 2% of difference.   
In the study of Oliveira et al., the features were not extracted from a supervised algorithm as in 
this work. Instead, the authors calculated the binding potential ratio of the striatum by taking the 
occipital and the cortex (excluding the basal ganglia) as a reference. Besides, in comparison with 
the present work and the other studies in Table 5.1, the Oliveira et al. study present the highest 
accuracy achieved.  
In Control vs SWEDD, although the classification using MRI slices presented higher results than 
SPECT slices, the CNN was not able to discriminate Control from SWEDD. For instance, the 
accuracy was 54.7% for MRI and SPECT slices 27_28_29, 65.3% and 62.8% with for MRI and 
SPECT slices encompassing the basal ganglia, respectively.  
Moreover, Cohen's Kappa results were less than 0.2 in all the cases which, according to McHugh, 
evidence that the CNN has a minimal level of agreement [213] with the PPMI database. Regarding 
the ROC curve, both MRI and SPECT slices 27_28_29 had AUC close to 0.50 that shows, 
according to Hosmer et al. [214], Control and SWEDD were not discriminated. 
The results obtained with SPECT DaTscan slices are accordance with the literature that indicates 
that SWEDD patients presented a normal DaTscan [12], [13], [15]. In comparison with the 
literature, the MRI classification showed lower accuracy (63.33%), sensitivity and specificity. 
For instance, the study of Singh et al. previously mentioned also classified Control vs SWEDD 
and obtained 99.4% accuracy in the age related group classification and 96.4% in the age 
unrelated group [169], as shown in Table 5.2. However, in that article the proportion of Control 
and SWEDD subjects are not the same (245 Control and 68), in contrast to this work that used a 
balanced train set (29 Control and 29 SWEDD) and test set (15 Control and 15 SWEDD). Besides, 
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it is important to note that the data sample used in this classification was lower than in Control vs 
PD since more subjects were considered.  
Concerning the classification of PD versus SWEDD, the CNN was able to discriminate those 
groups with 73.3% accuracy using the MRI slices of the mesencephalon and 76.00% accuracy 
using the SPECT slices of the basal ganglia. The highest accuracy result was obtained with 
SPECT slices 36_37_38 (93.3%). This result was not expected since in Control vs PD the highest 
accuracy result was obtained using SPECT slices of the basal ganglia. This may be related with 
the fact that each test set of the batches and between classification groups is different from the 
others because they are all result from a random selection of the data sample or because there may 
be something else in those slices than enable to discriminate PD vs SWEDD. Regarding the 
classification with the remaining slices, the CNN was not capable to discriminate PD versus 
SWEDD. 
The results of the Cohen’s Kappa indicate that the classification using slices 36_37_38 had perfect 
agreement level and it is the higher result obtained in this case.  
Table 5.2 Comparison of studies that performed classification of Control vs SWEDD 
Authors Control vs SWEDD (test sets results) 
Acc 
(%) 
Sen 
(%) 
Spe 
(%) 
AUC 
(%) 
Singh et al. 
[169] 
MRI images 
- Subjects: 
245 Control: 
155M, 90F, Age: 60.09±11.35 
68 SWEDD: 
48M/20F, Age: 61.53±9.59 
- Algorithms:  
SOM for Feature Extraction  
(features: intensity) 
LSSVM for training and classification 
(10 folds) 
It was performed two cases: 
    
1. Age Unrelated Groups 96.4 98.8 88.1 NA 
       2.    Age Related Groups 99.4 1 97.2 NA 
The present 
study 
MRI and SPECT slices  
- Datasets: 
2:1:1 - train, validation and test 
Train set: 29 PD/ 29 Control 
Validation set: 14 PD/ 14 Control 
Test set: 15 PD/ 15 Control     
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- Subjects: 
168 Control 
109M, 59F, Age: 60.0±11.0 years old 
58 SWEDD 
38M, 20F, Age: 62±10.0 years old 
- Algorithms:  
3D CNN 
(5 batches: Monte Carlo cross-validation) 
MRI mesencephalon slices 54.7 58.7 50.67 0.57 
SPECT basal ganglia slices 65.33 68.0 57.3 0.46 
Acc: Accuracy, Sen: Sensitivity, Spe: Specificity; AUC: Area Under the Curve; VOIs: Voxels of interest 
The results of the Cohen’s Kappa indicate that the classification using SPECT slices 36_37_38 
had, according to McHugh, perfect agreement level (ĸ = 0.87)[213] with the PPMI database. 
Using the SPECT slices of the basal ganglia, the results had a moderate level of agreement. 
However, the MRI slices of the mesencephalon lead to a weak level of agreement. 
The results of the ROC curve indicate that the classifier using SPECT DaTscan slices of the basal 
ganglia present higher AUC (ĸ = 0.72) than MRI basal ganglia slices (ĸ = 0.47) and consequently 
are greater discriminator.  
Physiologically, the SPECT results are in accordance with Marek et al. study that suggests that 
SWEDD patients do not have PD [216] since these patients did not present dopaminergic deficit 
[1], [12]. The results of the MRI slices suggest that the PD slices containing the mesencephalon 
are different from the SWEED slices.  
In comparison with Singh et al. study that also classified PD and SWEDD, the accuracy of the 
MRI slices was lower (73.33%) [169] as shown in Table 5.3. However, the authors did not use a 
balanced sample in the training set, which may have led to biased estimations (518 PD and 68 
SWEDD) [169].  
To summarize, the higher accuracy results as well as higher AUC common in the three 
classification groups was obtained using MRI slices 27_28_29 that correspond to mesencephalon 
and SPECT slices 39_40_41 that correspond to basal ganglia. Differences between batches or 
between classification slices results may be related with the fact that the test set was always 
created randomly for each batch.  
Moreover, unlike some studies expressed in Table 5.1 that use 3D images, the approach with 2D 
slices used in this work has the advantage that can be reproduced in clinical practice since the 
physicians make usage of 2D MRI images to aid in the diagnosis of brain diseases [27]. Besides, 
another benefit of using 2D slices, is the fact these images need smaller scanning (acquisition) 
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times than 3D images [194]. However, the disadvantage of the 2D slices usage is the fact these 
slices may contain less information than the volume of interest in 3D images.  
Table 5.3 Comparison of studies that performed classification of PD vs SWEDD 
Authors PD vs SWEDD (test sets results)  
Acc 
(%) 
Sen 
(%) 
Spe 
(%) 
AUC 
(%) 
Singh et al. 
[169] 
MRI images 
- Subjects: 
518 PD:  
346M/172F, Age: 61.79±9.58 
68 SWEDD: 
48M/20F, Age: 61.53±9.59 
- Algorithms:  
SOM for Feature Extraction  
(features: intensity) 
LSSVM for training and classification 
(10 folds) 
It was performed two cases: 
    
1. Age Unrelated Groups 94.6 99.2 60.7 NA 
       2.    Age Related Groups 98.9 99.5 95.7 NA 
The present 
study 
MRI and SPECT slices  
- Datasets: 
2:1:1 - train, validation and test 
Train set: 29 PD/ 29 Control 
Validation set: 14 PD/ 14 Control 
Test set: 15 PD/ 15 Control 
- Subjects: 
378 PD 
242M, 136F, Age: 62.0±10.0 
58 SWEDD 
38M, 20F, Age: 62±10.0 years old 
- Algorithms:  
2D CNN 
(5 batches: Monte Carlo cross-validation) 
2 cases: 
MRI mesecenphalon slices 73.3 58.7 50.7 0.84 
SPECT basal ganglia slices 86.0 68.0 57.3 0.90 
Acc: Accuracy, Sen: Sensitivity, Spe: Specificity; AUC: Area Under the Curve; VOIs: Voxels of interest 
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Concerning the CNN performance, unlike 3D images, the usage of 2D slices has the advantages 
of requiring less computing power and memory usage and training the classification models is 
less time-consuming. 
Singh et al. [167], Oliveira et al. [21] and Amoroso et al. [215] performed a classification based 
on SVM algorithm which achieved similar results to those obtained in this work with CNN, which 
indicates that both these approaches leads to higher accuracy results. Moreover, the feature 
extraction using other algorithm may also be time consuming. The drawback of the CNN is the 
fact that to training the studies typically are used several images. For instance, Lecun et al. [138] 
used 60,000 images to train the CNN, but it is also important to notice that the number of classes 
was 9 since it was intended to classify nine digits in contrast to this study that only was classified 
two classes.  
Thus, the main limitation of this dissertation was related with data sample, namely, the number 
of SWEDD subjects. PPMI database only have 58 SWEDD patients with both MRI and SPECT 
images. These 58 SWEDD subjects are significantly lower than the 169 Control subjects and 378 
PD-patients used.  As described in the methodology chapter, the number of subjects used in 
training the classification models is based on the number of subjects of the limiting group, that is, 
the group with less subjects in order to guarantee that in the classification step the same number 
of individuals of each group is analyzed. Because of that, only 58 Control and 58 PD-patients 
were considered in the Control vs SWEDD and PD vs SWEDD classification.  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Chapter 6 Conclusion and Future Work 
 
The main goal of this dissertation is to classify PD patients, SWEDD patients and Control 
(healthy) subjects using an approach based on MRI and SPECT slices and CNN. The results 
obtained allow to conclude that this objective was partially achieved since the CNN was able to 
distinguish PD from Controls and PD from SWEDD, but not Control from SWEDD. 
The discrimination of PD from Controls and PD from SWEDD was reached using specific slices 
that encompassed regions of interest associated with PD according to the literature. In particular, 
were MRI slices included the mesencephalon and SPECT slices included the basal ganglia, which 
are regions of interest known to be related with the dopamine deficit that PD-patients present. 
Moreover, according to the ROC curve results, these regions also lead to higher accuracy results 
in comparison with slices including other brain structures. However, unlike the expected, the MRI 
slices of the basal ganglia presented lower accuracy which may be related to the dataset and the 
number of subjects used.  
Regarding Control vs SWEDD, the CNN was not able to discriminate those subjects using SPECT 
slices which are in accordance with the literature wherein studies indicates that SWEDD patients 
have normal DaTscan. Furthermore, the findings using MRI slices of the mesencephalon shows 
there are no differences in Control slices and SWEDD slices.  
The classification of PD vs SWEDD suggests that SWEDD patients differ from PD patients in 
the fact that they had different MRI mesencephalon and different SPECT basal ganglia slices 
imaging patterns.  
Thus, the results obtained in this work suggest the fact that CNN is a useful tool for medical 
imaging classification based on imaging patterns. 
In comparison with other studies that make use of 3D images, this work has the advantage of 
using 2D slices which are the norm in clinical use and which are faster to acquire. Thus, this 
approach enables the usage of 2D images for diagnosis. Moreover, this also makes it possible to 
review the diagnosis using previously acquired data. The classification using the combination of 
2D images and CNN should in principle be simpler and faster in terms of computational effort 
enabling faster outputs obtained at the imaging console or Picture Archiving and Communication 
System (PACS).  
However, this methodology still needs improvement to be applied in the clinical environment. 
For instance, a lot of images were left out in the classification since it was used a balanced data 
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sample in the data sets. Additionally, data augmentation techniques can also be applied, such as 
mirroring, translations, and rotations, to increase the train set size.  
Furthermore, the classification with the axial anatomical view opens the way to the classification 
of the sagittal and coronal views as well.  
Moreover, the CNN performance can also be tested with the implementation of other loss and 
regularization functions, that were mentioned in subchapter 2.6. Regarding CNN architecture, this 
can be modified to accept more than three slices as input to perform, for instance, a multi-modality 
classification. 
To conclude, the approach proposed in this dissertation may be considered a promising and an 
innovative method for PD and SWEDD classification as well as other diseases based since it not 
only gives local information but also it indicates which medical imaging technique has higher 
accuracy.  
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Appendix A T1 – Weighted MRI and DaTscan acquisition 
 
Table A.1 T1-weighted MRI and DaTscan images sequence parameters and other critical characteristics. These characteristics  include repetition time, echo time, inversion 
time (for MRI) and dose (for SPECT) 
Technique Images Name Characteristics 
MRI Sag 3D FSPGR 
BRAVO straight 
Acquisition Plane: Sagittal; Acquisition Type = 3D; Manufacturer: GE Medical Systems: Size = 256 x 256 x 152 
mm3; Thickness = 1.2 mm; Voxels size = 1x1x1.2 mm3; Field Strength = 3T; Pulse Sequence = Gradient Echo 
 
MRI Sag 3D FSPGR 
BRAVO 
Acquisition Plane: Sagittal; Acquisition Type = 3D; Manufacturer: GE Medical Systems; Size = 256 x 256 x 152 
mm3; Thickness = 1.2 mm; Voxels size = 1x1x1.2 mm3; Field Strength = 3T; Pulse Sequence = Gradient Echo 
 
MRI SAG 3D T1 Acquisition Plane: Sagittal; Acquisition Type = 3D; Manufacturer: Philips Medical Systems; Size = 256 x 256 x 
170 mm3; Thickness = 1mm; Voxels size = 1x1x1 mm3; Field Strength = 1.5T; Pulse Sequence = Gradient Echo 
 
MRI MPRAGE 
GRAPPA 
Acquisition Plane: Sagittal; Acquisition Type = 3D; Manufacturer: SIEMENS; Size = 240 x 256 x 176 mm3; 
Thickness = 1mm; Voxels size = 1x1x1 mm3; Field Strength = 3T; Pulse Sequence = Gradient Echo /Inversion 
Recovery 
 
MRI AX T1 Acquisition Plane: Axial; Acquisition Type = 3D; Manufacturer: GE Medical Systems; Size = 512 x 512 x 84 mm3; 
Thickness = 2mm; Voxels size = 1x1x2 mm3; Field Strength = 1.5T; Pulse Sequence = Gradient Echo /Inversion 
Recovery 
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MRI AXIAL T1 3D 
MPRAGE 
Acquisition Plane: Axial; Acquisition Type = 3D; Manufacturer: SIEMENS; Size = 216 x 256 x 208 mm3; 
Thickness = 1mm; Voxels size = 1x1x1 mm3; Field Strength = 1.5T; Pulse Sequence = Gradient Echo /Inversion 
Recovery 
 
MRI Axial spgr Acquisition Plane: Axial; Acquisition Type = 3D; Manufacturer: GE Medical Systems; Size = 512 x 512 x 248 
mm3; Thickness = 1mm; Voxels size = 1x1x1 mm3; Field Strength = 1.5T; Pulse Sequence = Gradient Echo 
 
MRI SAG FSPGR 3D Acquisition Plane: Sagittal; Acquisition Type = 3D; Manufacturer: GE Medical Systems; Size = 256 x 256 x 248 
mm3; Thickness = 1.4mm; Voxels size = 1x1x1.4 mm3; Field Strength = 3T; Pulse Sequence = Gradient Echo 
 
MRI MPRAGE T1 SAG Acquisition Plane: Sagittal; Acquisition Type = 3D; Manufacturer: GE Medical Systems; Size = 256 x 256 x 176 
mm3; Thickness = 1.0 mm; Voxels size = 1x1x1.4 mm3; Field Strength = 3T; Pulse Sequence = Gradient Echo 
 
MRI MPRAGE SAG Acquisition Plane: Sagittal; Acquisition Type = 3D; Manufacturer: SIEMENS; Size = 512 x 512 x 80 mm3; 
Thickness = 2 mm; Voxels size = 1x1x2 mm3; Field Strength = 1.5T; Pulse Sequence = Gradient Echo/Inversion 
Recovery 
 
MRI SAG T1 3D 
FSPGR 
Acquisition Plane: Sagittal; Acquisition Type = 3D; Manufacturer: SIEMENS; Size = 256 x 256 x 98 mm3; 
Thickness = 1.5 mm; Voxels size = 1x1x1.5 mm3; Field Strength = 1.5T; Pulse Sequence = Gradient Echo 
 
MRI SAG SPGR Acquisition Plane: Sagittal; Acquisition Type = 3D; Manufacturer: GE Medical Systems; Size = 256 x 256 x 98 
mm3; Thickness = 1.5 mm; Voxels size = 1x1x1.5 mm3; Field Strength = 0.7T; Pulse Sequence = Gradient Echo 
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MRI 3D SAG Acquisition Plane: Sagittal; Acquisition Type = 3D; Manufacturer: Philips Medical Systems; Size = 256 x 256 x 
154 mm3; Thickness = 1.2 mm; Voxels size = 1x1x1.2 mm3; Field Strength = 1.5T; Pulse Sequence = Gradient 
Echo 
 
MRI FSPGR 3D SAG Acquisition Plane: Sagittal; Acquisition Type = 3D; Manufacturer: GE Medical Systems; Size = 256 x 256 x 152 
mm3; Thickness = 1.2 mm; Voxels size = 1x1x1.2 mm3; Field Strength = 1.5T; Pulse Sequence = Gradient Echo 
 
MRI SAG FSPGR 
BRAVO 
Acquisition Plane: Sagittal; Acquisition Type = 3D; Manufacturer: GE Medical Systems; Size = 256 x 256 x 152 
mm3; Thickness = 1.2 mm; Voxels size = 1x1x1.2 mm3; Field Strength = 3T; Pulse Sequence = Gradient Echo 
 
SPECT DaTscan Size = 109 x 91 x 91 mm3; Voxels size = 2x2x2 mm3; Target dose for subjects = 185 MBq or 5.0 mCi of DaTSCAN™ 
Dose range for injection = 111 to 185 MBq; Raw projection data dimension = 128 x 128 matrix stepping each 3 
degrees for a total of 120 projections or 4 degrees for a total of 90 projections 
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Appendix B: Accuracy Results  
 
Table B. 1 Accuracy results obtained in the classification of Control vs PD with MRI slices 
Slices Accuracy 
Batch1 
(%) 
Batch2 
(%) 
Batch3 
(%) 
Batch4 
 (%) 
Batch5 
(%) 
Avg ± std 
(%) 
Slices 21_22_23 
Total 56.0 60.7 47.6 39.3 50.0 50.7±7.3 
Control 54.8 50.0 47.6 45.2 54.8 50.5±3.8 
PD 57.1 71.4 47.6 33.3 45.2 51.0±12.7 
Slices 24_25_26 
Total 56.0 60.7 47.6 39.3 50.0 50.7±6.7 
Control 54.8 50.0 47.6 45.2 54.8 50.5±3.5 
PD 57.1 71.4 47.6 33.3 45.2 51.0±11.6 
Slices 27_28_29 
Total 97.6 97.6 95.2 97.6 98.8 97.4±1.2 
Control 95.2 95.2 90.5 95.2 97.6 94.8±2.3 
PD 100.0 100.0 100.0 100.0 100.0 100.0±0.0 
Slices 30_31_32 
Total 46.4 69.0 54.8 54.8 57.1 56.4±7.3 
Control 57.1 61.9 54.8 52.4 66.7 58.6±5.1 
PD 35.7 76.2 54.8 57.1 47.6 54.3±13.2 
Slices 33_34_35 
Total 52.4 51.2 53.6 50.0 53.6 52.1±1.4 
Control 50.0 54.8 57.1 40.5 50.0 50.5±5.7 
PD 54.8 47.6 50.0 59.5 57.1 53.8±4.4 
Slices 36_37_38 
Total 53.6 53.6 58.3 48.8 48.8 52.6±3.6 
Control 52.4 59.5 54.8 54.8 59.5 56.2±2.9 
PD 54.8 47.6 61.9 42.9 38.1 49.0±8.5 
Slices 39_40_41 
Total 48.8 40.5 45.2 47.6 46.4 45.7±2.9 
Control 38.1 35.7 50.0 54.8 38.1 43.3±7.6 
PD 59.5 45.2 40.5 40.5 54.8 48.1±7.7 
Slices 42_43_44 
Total 44.0 42.9 42.9 54.8 45.2 46.0±4.5 
Control 45.2 42.9 45.2 54.8 47.6 47.1±4.1 
PD 42.9 42.9 40.5 54.8 42.9 44.8±5.1 
Slices 45_46_47 
Total 53.6 50.0 47.6 47.6 51.2 50.0±2.3 
Control 59.5 52.4 47.6 45.2 54.8 51.9±5.1 
PD 47.6 47.6 47.6 50.0 47.6 48.1±1.0 
Avg: Average; std: Standard Deviation 
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Table B. 2 Accuracy results obtained in the classification of Control vs PD with SPECT slices 
Slices Accuracy 
Batch1 
(%) 
Batch2 
(%) 
Batch3 
(%) 
Batch4 
(%) 
Batch5 
(%) 
Avg ±std 
(%) 
 Total 50.0 65.5 59.5 64.3 57.1 59.3±5.6 
Slices 21_22_23 PD 47.6 71.4 54.8 64.3 59.5 59.5±8.1 
 SWEDD 52.4 59.5 64.3 64.3 54.8 59.0±4.9 
 Total 66.7 58.3 59.5 60.7 51.2 59.3±5.0 
Slices 24_25_26 Control 61.9 69.0 59.5 71.4 52.4 62.9±6.8 
 PD 71.4 47.6 59.5 50.0 50.0 55.7±8.9 
 Total 57.1 63.1 63.1 61.9 64.3 61.9±2.5 
Slices 27_28_29 Control 61.9 66.7 57.1 54.8 66.7 61.4±4.9 
 PD 52.4 59.5 69.0 69.0 61.9 62.4±6.3 
 Total 75.0 79.8 67.9 72.6 81.0 75.2±4.8 
Slices 30_31_32 Control 78.6 81.0 64.3 64.3 92.9 76.2±10.9 
 PD 71.4 78.6 71.4 81.0 69.0 74.3±4.6 
 Total 71.4 78.6 78.6 79.8 84.5 78.6±4.2 
Slices 33_34_35 Control 61.9 73.8 76.2 73.8 88.1 74.8±8.3 
 PD 81.0 83.3 81.0 85.7 81.0 82.4±1.9 
 Total 92.9 91.7 88.1 86.9 86.9 89.3±2.5 
Slices 36_37_38 Control 95.2 92.9 90.5 78.6 90.5 89.5±5.8 
 PD 90.5 90.5 85.7 95.2 83.3 89.0±4.2 
 Total 95.2 97.6 89.3 91.7 88.1 92.4±3.6 
Slices 39_40_41 Control 95.2 97.6 90.5 92.9 83.3 91.9±4.9 
 PD 95.2 97.6 88.1 90.5 92.9 92.9±3.4 
 Total 85.7 86.9 83.3 85.7 85.7 85.5±1.2 
Slices 42_43_44 Control 92.9 88.1 92.9 85.7 85.7 89.0±3.2 
 PD 78.6 85.7 73.8 85.7 85.7 81.9±4.9 
 Total 69.0 71.4 82.1 71.4 73.8 73.6±4.5 
Slices 45_46_47 Control 69.0 64.3 78.6 66.7 81.0 71.9±6.6 
 PD 69.0 78.6 85.7 76.2 66.7 75.2±6.8 
Avg: Average; std: Standard Deviation 
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Table B. 3 Accuracy results obtained in the classification of Control vs SWEDD with MRI slices 
Slices Accuracy 
Batch1 
(%) 
Batch2 
(%) 
Batch3 
(%) 
Batch4 
(%) 
Batch5 
(%) 
Avg±Std 
(%) 
 Total 46.7 50.0 60.0 60.0 73.3 58.0±9.3 
Slice-21_22_23 PD 53.3 66.7 66.7 80.0 93.3 72.0±13.6 
 SWEDD 40.0 33.3 53.3 40.0 53.3 44.0±8.0 
 Total 63.3 83.3 60.0 66.7 53.3 65.3±10.0 
Slice-24-25-26 Control 46.7 86.7 80.0 60.0 46.7 64.0±16.7 
 SWEDD 80.0 80.0 40.0 73.3 60.0 66.7±15.2 
 Total 50.0 73.3 46.7 46.7 56.7 54.7±10.0 
Slice-27-28-29 Control 40.0 73.3 40.0 46.7 53.3 50.7±12.4 
 SWEDD 60.0 73.3 53.3 46.7 60.0 58.7±8.8 
 Total 60.0 40.0 53.3 53.3 63.3 54.0±8.0 
Slice-30-31-32 Control 66.7 46.7 46.7 53.3 80.0 58.7±12.9 
 SWEDD 53.3 33.3 60.0 53.3 46.7 49.3±9.0 
 Total 70.0 53.3 56.7 53.3 46.7 56.0±7.7 
Slices 33_34_35 Control 66.7 53.3 40.0 46.7 60.0 53.3±9.4 
 SWEDD 73.3 53.3 73.3 60.0 33.3 58.7±14.8 
 Total 50.0 63.3 46.7 46.7 70.0 55.3±9.6 
Slices 36_37_38 Control 40.0 86.7 40.0 53.3 66.7 57.3±17.7 
 SWEDD 60.0 40.0 53.3 40.0 73.3 53.3±12.6 
 Total 60.0 63.3 63.3 66.7 73.3 65.3±4.5 
Slices 39_40_41 Control 73.3 60.0 60.0 60.0 73.3 65.3±6.5 
 SWEDD 46.7 66.7 66.7 73.3 73.3 65.3±9.8 
 Total 46.7 50.0 63.3 63.3 60.0 56.7±7.0 
Slice-42-43-44 Control 53.3 53.3 66.7 60.0 86.7 64.0±12.4 
 SWEDD 40.0 46.7 60.0 66.7 33.3 49.3±12.4 
 Total 73.3 60.0 60.0 63.3 60.0 63.3±5.2 
Slice-45_46_47 Control 73.3 66.7 46.7 46.7 66.7 60.0±11.2 
 SWEDD 73.3 53.3 73.3 80.0 53.3 66.7±11.2 
Avg: Average; std: Standard Deviation 
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Table B. 4 Accuracy results obtained in the classification of Control vs SWEDD with SPECT slices 
Slices Accuracy 
Batch1 
(%) 
Batch2 
(%) 
Batch3 
(%) 
Batch4 
(%) 
Batch5 
(%) 
Avg±std 
(%) 
 Total 63.3 60.0 70.0 43.3 60.0 59.3±8.8 
Slices 21_22_23 PD 73.3 66.7 60.0 46.7 53.3 60.0±9.4 
 SWEDD 53.3 53.3 80.0 40.0 66.7 58.7±13.6 
 Total 53.3 56.7 66.7 60.0 60.0 59.3±4.4 
Slices 24-25-26 Control 60.0 66.7 66.7 60.0 66.7 64.0±3.3 
 SWEDD 46.7 46.7 66.7 60.0 53.3 54.7±7.8 
 Total 40.0 56.7 43.3 63.3 70.0 54.7±11.5 
Slices 27-28-29 Control 53.3 53.3 40.0 66.7 86.7 60.0±15.8 
 SWEDD 26.7 60.0 46.7 60.0 53.3 49.3±12.4 
 Total 50.0 40.0 53.3 40.0 46.7 46.0±5.3 
Slices 30_31_32 Control 46.7 46.7 53.3 33.3 40.0 44.0±6.8 
 SWEDD 53.3 33.3 53.3 46.7 53.3 48.0±7.8 
 Total 60.0 50.0 33.3 56.7 56.7 51.3±9.6 
Slices 33_34_35 Control 66.7 66.7 6.7 46.7 60.0 49.3±22.5 
 SWEDD 53.3 33.3 60.0 66.7 53.3 53.3±11.2 
 Total 40.0 63.3 40.0 56.7 43.3 48.7±9.6 
Slices 36_37_38 Control 33.3 60.0 20.0 73.3 33.3 44.0±19.6 
 SWEDD 46.7 66.7 60.0 40.0 53.3 53.3±9.4 
 Total 63.3 53.3 60.0 56.7 80.0 62.7±9.3 
Slices 39_40_41 Control 73.3 33.3 60.0 40.0 80.0 57.3±18.2 
 SWEDD 53.3 73.3 60.0 73.3 80.0 68.0±9.8 
 Total 40.0 66.7 56.7 53.3 43.3 52.0±9.6 
Slices 42_43_44 Control 33.3 66.7 46.7 60.0 26.7 46.7±15.2 
 SWEDD 46.7 66.7 66.7 46.7 60.0 57.3±9.0 
 Total 53.3 63.3 60.0 56.7 50.0 56.7±4.7 
Slices 45_46_47 Control 46.7 60.0 66.7 53.3 46.7 54.7±7.8 
 SWEDD 60.0 66.7 53.3 60.0 53.3 58.7±5.0 
Avg: Average; std: Standard Deviation 
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Table B. 5Accuracy results obtained in the classification of PD vs SWEDD with MRI slices 
Slices Accuracy 
Batch1 
(%) 
Batch2 
(%) 
Batch3 
(%) 
Batch4 
(%) 
Batch5 
(%) 
Avg±std 
(%) 
 Total 56.7 40.0 50.0 56.7 40.0 48.7±7.5 
Slices 21_22_23 PD 60.0 53.3 66.7 26.7 26.7 46.7±16.9 
 SWEDD 53.3 26.7 33.3 86.7 53.3 50.7±20.9 
 Total 50.0 56.7 46.7 53.3 56.7 52.7±3.9 
Slices 24-25-26 PD 40.0 66.7 33.3 53.3 46.7 48.0±11.5 
 SWEDD 60.0 46.7 60.0 53.3 66.7 57.3±6.8 
 Total 53.3 60.0 63.3 66.7 60.0 60.7±4.4 
Slices 27-28-29 PD 53.3 66.7 46.7 46.7 73.3 57.3±10.8 
 SWEDD 53.3 53.3 80.0 86.7 46.7 64.0±16.1 
 Total 63.3 63.3 53.3 66.7 63.3 62.0±4.5 
Slices 30_31_32 PD 66.7 60.0 53.3 60.0 73.3 62.7±6.8 
 SWEDD 60.0 66.7 53.3 73.3 53.3 61.3±7.8 
 Total 93.3 73.3 80.0 73.3 80.0 80.0±7.3 
Slices 33_34_35 PD 93.3 93.3 73.3 73.3 93.3 85.3±9.8 
 SWEDD 93.3 53.3 86.7 73.3 66.7 74.7±14.2 
 Total 96.7 93.3 96.7 86.7 93.3 93.3±3.7 
Slices 36_37_38 PD 100.0 86.7 93.3 80.0 93.3 90.7±6.8 
 SWEDD 93.3 100.0 100.0 93.3 93.3 96.0±3.3 
 Total 93.3 83.3 90.0 83.3 80.0 86.0±4.9 
Slices 39_40_41 PD 93.3 80.0 93.3 80.0 80.0 85.3±6.5 
 SWEDD 93.3 86.7 86.7 86.7 80.0 86.7±4.2 
 Total 70.0 63.3 83.3 80.0 83.3 76.0±8.0 
Slices 42_43_44 PD 66.7 53.3 100.0 73.3 93.3 77.3±17.2 
 SWEDD 73.3 73.3 66.7 86.7 73.3 74.7±6.5 
 Total 56.7 66.7 70.0 83.3 76.7 70.7±9.0 
Slices 45_46_47 PD 66.7 60.0 66.7 66.7 66.7 65.3±2.7 
 SWEDD 46.7 73.3 73.3 100.0 86.7 76.0±17.7 
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Table B. 6 Accuracy results obtained in the classification of PD vs SWEDD with SPECT slices 
Slices Accuracy 
Batch1 
(%) 
Batch2 
(%) 
Batch3 
(%) 
Batch4 
(%) 
Batch5 
(%) 
Avg±std 
(%) 
 Total 50.0 56.7 56.7 46.7 46.7 51.3±4.5 
Slices 21_22_23 PD 40.0 60.0 60.0 40.0 60.0 52.0±9.8 
 SWEDD 60.0 53.3 53.3 53.3 33.3 50.7±9.0 
 Total 80.0 80.0 56.7 53.3 76.7 69.3±11.8 
Slices 24_25_26 PD 80.0 73.3 46.7 46.7 80.0 65.3±15.4 
 SWEDD 80.0 86.7 66.7 60.0 73.3 73.3±9.4 
 Total 66.7 76.7 73.3 76.7 73.3 73.3±3.7 
Slices 27_28_29 PD 86.7 93.3 66.7 86.7 73.3 81.3±9.8 
 SWEDD 46.7 60.0 80.0 66.7 73.3 65.3±11.5 
 Total 63.3 46.7 63.3 53.3 63.3 58.0±6.9 
Slices 30_31_32 PD 60.0 33.3 60.0 60.0 66.7 56.0±11.6 
 SWEDD 66.7 60.0 66.7 46.7 60.0 60.0±7.3 
 Total 60.0 56.7 56.7 66.7 70.0 62.0±5.4 
Slices 33_34_35 PD 53.3 60.0 60.0 60.0 60.0 58.7±2.7 
 SWEDD 66.7 53.3 53.3 73.3 80.0 65.3±10.7 
 Total 63.3 53.3 60.0 53.3 70.0 60.0±6.3 
Slices 36_37_38 PD 40.0 40.0 40.0 53.3 80.0 50.7±15.5 
 SWEDD 86.7 66.7 80.0 53.3 60.0 69.3±12.4 
 Total 40.0 60.0 53.3 46.7 73.3 54.7±11.5 
Slices 39_40_41 PD 33.3 73.3 60.0 40.0 60.0 53.3±14.6 
 SWEDD 46.7 46.7 46.7 53.3 86.7 56.0±15.5 
 Total 56.7 53.3 60.0 56.7 56.7 56.7±2.1 
Slices 42_43_44 PD 33.3 46.7 53.3 53.3 53.3 48.0±7.8 
 SWEDD 80.0 60.0 66.7 60.0 60.0 65.3±7.8 
 Total 60.0 50.0 66.7 53.3 56.7 57.3±5.7 
Slices 45_46_47 PD 46.7 46.7 60.0 53.3 53.3 52.0±5.0 
 SWEDD 73.3 53.3 73.3 53.3 60.0 62.7±9.0 
Avg: Average; std: Standard Deviation 
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Figure C. 1 Example from one control subject of the 79 slices obtained with 3D T1-Weighted MRI images 
division in Axial plane. 
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Figure C. 2 Example from one control subject of the 79 slices obtained with DatTscan SPECT images 
division in Axial plane. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
64 65 68 67 66 69 
71 72 74 73 
70 
75 76 77 
79 78 
